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 Executive Functioning and Adherence to Antihypertensive Medications  
Among a Sample of Older Adults 
 
Lauren R. Strainge, Ph.D. 
University of Connecticut, 2020 
 
 
Objective: Consistent medication adherence is critical for the effective management of 
hypertension among the elderly. Executive functioning (EF), higher-order cognitive abilities that 
include set-shifting, information updating, and inhibition, have been associated with medication 
adherence among other populations, but the role of these processes in adherence to medications in 
older adults with hypertension is unknown. A conceptual model of the ways in which specific 
executive processes could impact adherence is presented, and specific executive processes and 
broad EF were examined as predictors of adherence to antihypertensive medication over a 3-month 
study of hypertension and cognition in the elderly.  
 
Method: 76 adults with hypertension over age 75 completed baseline neuropsychological testing, 
including multiple tests of EF: Trail Making Test, Part B, the Wechsler Adult Intelligence Scales-
Fourth Edition Digit Span Backwards task, the Stroop Color-Word Test, and phonemic/letter 
fluency and semantic/category fluency tasks. Medication adherence was measured by pill count 
(proportion of prescribed pills returned). 
  
Results: Participants in the study were largely adherent, and missed an average of just 6.32% of 
their doses of antihypertensive medication in the three months following cognitive testing (SD = 
10.35). Composite EF scores were significantly predictive of better adherence to 
antihypertensive medications in the three months following baseline neuropsychological testing 
(Exp() = 0.926; 95% CI: 0.870–0.985; p = 0.014), as were performances on a measure of 
information updating/monitoring (difference between Digits Backward and Digits Forward 
scores: Exp() = 0.907; 95% CI: 0.828–0.994; p = 0.037) and a measure of inhibition (Stroop 
Interference scores: Exp() = 0.960; 95% CI: 0.930–0.991; p = 0.013). Other tests of EF were 
not significantly associated with adherence.  
 
Conclusion: These findings lend partial support to the proposed conceptual model and suggest that 
screening for deficits in broad EF, and information updating and inhibitory control specifically, 
may help to identify and perhaps intervene with patients at risk for suboptimal antihypertensive 
adherence. 
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Executive Functioning and Adherence to Antihypertensive Medications  
Among a Sample of Older Adults 
 
Despite decades of progress in the prevention, detection, and treatment of high blood 
pressure (BP), known as hypertension (HTN), this illness continues to present a major public 
health challenge (Fryar, Ostchega, Hales, Zhang, & Kruszon-Moran, 2017). Defined by the 
American Cardiology College and American Heart Association as systolic blood pressure (BP) 
greater than 130 mm Hg and/or diastolic BP greater than 80 mm Hg (Whelton et al., 2018), HTN 
is the most prevalent of all non-communicable chronic diseases throughout the world and has been 
designated a global public health crisis by the World Health Organization (Benjamin et al., 2017, 
2018; World Health Organization (WHO), 2013a). 
HTN affects an estimated 103 million Americans, approximately 46% of the nation’s 
population (Benjamin et al., 2018). HTN prevalence estimates within the United States have 
increased dramatically in the past five years (Benjamin et al., 2018; Dorans, Mills, Liu, & He, 
2018; Fryar et al., 2017). While a portion of this increase can be attributed to changing guidelines 
regarding the diagnosis and treatment of HTN (Whelton et al., 2018), long-term population trends, 
including the aging of the “Baby Boomer” generation, increasing lifespans, and lifestyle factors 
such as poor diet and exercise habits are also major contributors (Benjamin et al., 2018; Dorans et 
al., 2018). Based on these trends, epidemiological evidence suggests that the prevalence of HTN 
will likely continue to increase in the near future (Benjamin et al., 2018; Dorans et al., 2018; 
Federal Interagency Forum on Aging-Related Statistics, 2012).  
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The Health and Economic Impact of HTN 
Often referred to as a “silent killer,” HTN, though generally asymptomatic in itself, is a 
dangerous chronic disease and a major risk factor for a host of other chronic illnesses, as well as 
all-cause morbidity and mortality (Lewington, Clarke, Qizilbash, Peto, & Collins, 2002; Moore, 
2005; Wei, George, Chang, & Hicks, 2017). Because of the diffuse nature of the cardiovascular 
system, HTN can impact nearly every other bodily system. As denoted in its name, high BP exists 
when blood exerts excess pressure on the blood vessel walls. Over time, the increased force of 
circulating blood against artery walls due to HTN causes damage to the vascular system in organ 
systems throughout the body (Abraham et al., 2016; De Silva & Faraci, 2016; Hu, De Silva, Chen, 
& Faraci, 2017; McMaster, Kirabo, Madhur, & Harrison, 2015). These vascular changes are then 
associated with increased risk for a host of cardiovascular events and chronic illnesses, including 
coronary heart disease, myocardial infarction, stroke, heart failure, peripheral artery disease, 
chronic kidney disease, and dementia, among others (Benjamin et al., 2018; Foley et al., 1996; 
Franklin, 2012; Jager et al., 1999; Lloyd-Jones et al., 2009; MacMahon et al., 1990; Posner et al., 
2002; Yu, Zhou, & Cai, 2011).  
Because of its prevalence and detrimental impact throughout the body, HTN is the most 
common cause of cardiovascular disease-related deaths, both in the United States and worldwide 
(Benjamin et al., 2018; Mills et al., 2016; Salem et al., 2018). Between 2005 and 2015, death rates 
from HTN increased by nearly 11%, and the total number of deaths primarily attributable to HTN 
increased nearly 38% (Benjamin et al., 2018). Importantly, this represents less than one-fifth of 
deaths in which HTN is believed to have played at least a partial causal role, which numbered 
nearly 430,000 deaths in 2014 alone (Benjamin et al., 2018; Kochankek, Muphy, Xu, & Tejada-
Vera, 2016). 
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HTN also has a significant economic cost. Recent estimates indicate that in the United 
States, hypertensive patients have nearly $2,000 more in annual medical expenditures compared 
to their non-hypertensive peers, even after controlling for numerous demographic factors, 
including medical comorbidities, geographic location, income, and insurance status (Kirkland et 
al., 2018). This difference reflects higher costs across the healthcare system, including outpatient 
costs (nearly 2 times higher), inpatient costs (2.5 times higher), and prescription medication 
expenditures (nearly 3 times higher) (Kirkland et al., 2018). Overall healthcare costs associated 
with HTN total an estimated $131 billion each year in the United States alone.  
The significant and growing health risks and economic costs associated with HTN have 
made it a crucial target for medical intervention over the last several decades, resulting in a large 
body of biomedical and behavioral medicine research. Long-term management of this dangerous 
chronic disease has become a primary public health goal in the United States and abroad (Angell, 
De Cock, & Frieden, 2012; Frieden & Berwick, 2011; WHO, 2013a, 2013b). A large proportion 
of research in HTN has focused on a segment of the population known to be at increased risk, the 
elderly. 
HTN in the Elderly 
HTN prevalence increases significantly with age (Lionakis, Mendrinos, Sanidas, Favatas, 
& Georgopoulou, 2012; Murai, Takase, Sugiura, Ohte, & Dohi, 2017; Yazdanyar & Newman, 
2009), and age is considered one of the primary risk factors for HTN (Benjamin et al., 2018; 
Yazdanyar & Newman, 2009). Recent estimates suggest that more than 67% of Americans aged 
60 and older meet diagnostic criteria for HTN, compared to just 7.5% of Americans under age 40 
(Benjamin et al., 2018; Fryar et al., 2017). Furthermore, these rates appear to be increasing, 
particularly for very elderly adults. In 2010, prevalence rates for HTN among adults age 80 or 
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older were estimated at 76.5%, a substantial increase from 69.2% in 1994 (Benjamin et al., 2018). 
HTN incidence also increases dramatically as individuals age; individuals who maintain normal 
BP through age 55 nevertheless have a 90% chance of developing HTN in their remaining lifespan 
(Levy, Larson, Vasan, Kannel, & Ho, 1996). Indeed, the aging of the population is considered a 
primary factor in the increasing prevalence of HTN in the United States (Dorans et al., 2018).  
HTN and Chronic Disease. The increased incidence of HTN among older adults also 
corresponds to increased risk for associated chronic disease, particularly cardiovascular and 
cerebrovascular disease (Babatsikou & Zavitsanou, 2010; Lionakis et al., 2012; Posner et al., 2002; 
Yazdanyar & Newman, 2009). For older adults with HTN, lifetime risk of cardiovascular disease 
is 60.2%, compared to 44.6% among non-hypertensive elderly individuals, and those with HTN 
have been found to develop cardiovascular disease an average of five years earlier than their 
normotensive peers (Rapsomaniki et al., 2014). In addition, more then 80% of cardiovascular 
disease-related deaths occur in patients over age 65, and elderly patients with HTN have a 
significantly higher prevalence of myocardial infarction and more than double the rate of heart 
failure compared to elderly patients without HTN (Franklin et al., 2001; Kannel, 2003; Levy et al., 
1996; Lloyd-Jones et al., 2009; Messerli, Rimoldi, & Bangalore, 2017; Rapsomaniki et al., 2014).  
Neurologically, HTN among the elderly is a major risk factor for both ischemic stroke and 
cerebral hemorrhage (Lionakis et al., 2012; Rapsomaniki et al., 2014; Yu et al., 2011). Indeed, age 
and HTN are the two strongest risk factors for stroke, with even greater risk among elderly women 
(Lewington et al., 2002; Rapsomaniki et al., 2014). Older adults with HTN are 3-4 times more 
likely to experience a stroke compared to normotensive peers, and more than half of strokes can 
be attributed to HTN (Gorelick, 2002; Lawes, Hoorn, & Rodgers, 2008; Lionakis et al., 2012).  
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The same mechanisms that increase risk for stroke (i.e., large vessel cerebrovascular 
disease) among hypertensive older adults also increase risk for small vessel disease. Over time, 
HTN contributes to chronic microvascular ischemic changes that damage white matter axonal 
connections in the brain (Gouw et al., 2010; O’Sullivan, 2008). Beyond aging, HTN is the single 
most significant cardiovascular risk factor for subsequent small vessel cerebrovascular disease 
among older adults (Abraham et al., 2016; Khan, Porteous, Hassan, & Markus, 2007). If severe 
enough, these changes can manifest as vascular dementia, with risk of even greater cognitive 
decline when BP remains uncontrolled (Vinyoles, De la Figuera, & Gonzalez-Segura, 2008). HTN 
also appears to interact with other vascular risk factors, such as high cholesterol, to further increase 
risk for vascular dementia (Posner et al., 2002). 
Taken together, these findings provide strong causal evidence for the significantly greater 
morbidity and mortality rates for elderly HTN patients compared to elderly individuals without 
HTN (Babatsikou & Zavitsanou, 2010; Benjamin et al., 2018; Rapsomaniki et al., 2014). While a 
full discussion of the role of HTN in chronic disease among older adults is outside the scope of the 
current study, this brief summary highlights the severe and detrimental impact of HTN on health 
and functioning among older adults.  
Treatment of HTN. Fortunately, HTN can be managed effectively with a number of 
available medications. Active pharmacological treatment can bring elevated BP “under control,” 
defined as having both a systolic BP of less than 130 mm Hg and a diastolic BP of less than 80 
mm Hg (Whelton et al., 2018). HTN control is associated with significant health benefits. 
Substantial meta-analytic evidence from numerous large-scale longitudinal studies has indicated 
that pharmacological control of HTN significantly reduces risk for cardiovascular disease, stroke, 
and total mortality for both elderly (age 60 and older) and very elderly (age 80 and older) patients 
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(Aronow et al., 2011; Beckett et al., 2012; Bejan-Angoulvant et al., 2010; Bulpitt et al., 2003; 
Staessen et al., 2000; Wright et al., 2015). Indeed, some trials have even been terminated early 
because of the strong positive intervention effect of intensive HTN treatment on all-cause mortality 
(Wright et al., 2015).  
In a meta-analysis of randomized control trials among older adults age 80 and older, 
antihypertensive treatment reduced risk of cardiovascular events by 27% (Bejan-Angoulvant et al., 
2010). Risk of stroke was reduced by 35%, and risk of heart failure was reduced by a full 50% 
(Bejan-Angoulvant et al., 2010). In addition, among these very elderly patients, treatment of HTN 
has been shown to reduce incidence of all-cause mortality by more than 20% (Aronow et al., 2011). 
Based on these findings, treatment of HTN is highly recommended among a majority of 
hypertensive older adults (Aronow et al., 2011; Bejan-Angoulvant et al., 2010; Qaseem et al., 
2017; Staessen et al., 2000). 
Medication Adherence in HTN. Yet despite the availability of effective treatment tools, 
more than 36% of HTN patients receiving pharmacological treatment continue to have 
uncontrolled BP (Fryar et al., 2017; Ong, Cheung, Man, Lau, & Lam, 2007). While 
antihypertensive medications can be highly efficacious, these drugs need to be taken consistently 
in order to be fully effective (Aronow et al., 2011; Frishman, 2007). In a study comparing patients 
with high adherence (80% or more) to those with low (less than 40%) or intermediate adherence 
(40-79%), only those with high adherence experienced a benefit in terms of reduced cardiovascular 
events (Mazzaglia et al., 2009). As such, medication adherence, or taking medications as 
prescribed, constitutes a vital component of effective HTN management (Borzecki, Oliveria, & 
Berlowitz, 2005; WHO, 2003). 
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Unfortunately, evidence suggests that a large proportion of HTN patients exhibit 
suboptimal adherence, and frequently fail to take their antihypertensive medications as directed 
(Borzecki et al., 2005; Cramer, Benedict, Muszbek, Keskinaslan, & Khan, 2008; Krousel-Wood, 
Muntner, Islam, Morisky, & Webber, 2009; Peacock & Krousel-Wood, 2017a). As many as half 
of new HTN patients cease treatment within the first year despite on-going need for medication, 
and more than 10% of HTN patients miss a scheduled dose on any given day (Vrijens, Vincze, 
Kristanto, Urquhart, & Burnier, 2008). Indeed, in a large-scale study of pharmacy records, nearly 
16% of antihypertensive prescriptions went entirely unfilled, affecting more than 24% of patients 
(Cooke, Xing, Lee, & Belletti, 2011).  
Among these patients, poor adherence contributes to a host of negative short- and long-
term health outcomes, including persistent HTN and low BP control (Borzecki et al., 2005; 
Krousel-Wood et al., 2009; Naderi, Bestwick, & Wald, 2012; Weitzman, Chodick, Shalev, 
Grossman, & Grossman, 2014). Low adherence is the most common cause of apparent “treatment-
resistant” HTN, defined as uncontrolled BP while taking three or more classes of antihypertensive 
medication (Carey, Sakhuja, Calhoun, Whelton, & Muntner, 2019; de Jager, van Maarseveen, 
Bots, & Blankestijn, 2018; Jung et al., 2013). While estimates have suggested that the prevalence 
of treatment-resistance HTN could range from 10-35% of HTN patients, new evidence suggests 
that this figure may be closer to 2% after correcting for poor adherence (Carey et al., 2019; Persell, 
2011; Smith, Gurka, Winterstein, Pepine, & Cooper‐DeHoff, 2019; Weitzman et al., 2014). 
Indeed, a comparison of “treatment-resistant” HTN studies found that the proportion of 
participants in these cohorts with poor adherence ranged from 23% to nearly 66% (Berra et al., 
2016). This evidence indicates that with high levels of adherence to their anti-hypertensive 
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medication regimens, the large majority of individuals with HTN can achieve BP control and its 
associated health benefits.  
The Cost of Poor HTN Adherence. Beyond poor BP control, low adherence contributes to 
higher rates of associated cardiovascular and cerebrovascular disease, as well as increased risk of 
hospitalization (Gehi, Ali, Na, & Whooley, 2007; Kettani et al., 2009; Kim et al., 2016a; Krousel-
Wood et al., 2009; Naderi et al., 2012; Shin et al., 2013; Will, Zhang, Ritchey, & Loustalot, 2016). 
Poor adherence to antihypertensives has been associated with a 22% increase in risk for incident 
cerebrovascular disease (Kettani et al., 2009), and risk for incident cardiovascular events (e.g., 
myocardial infarctions) is more than double among patients who are non-adherent to 
antihypertensives compared to patients who maintain adherence, even after adjusting for baseline 
cardiac disease severity, cardiac risk factors, and depressive symptoms (Gehi et al., 2007). 
Similarly, in a large-scale study that adjusted for age, sex, and multiple medical co-morbidities, 
risk of hospitalization for cardiovascular disease increased for patients as adherence decreased, 
with greater risk of hospitalization in patients who demonstrated intermediate adherence (50-80% 
of prescribed doses) and even higher hospitalization risk in patients whose adherence was poor (< 
50% of prescribed doses) (Kim et al., 2016a). In the same study, individuals with suboptimal 
antihypertensive adherence were at particularly increased risk for cerebral hemorrhage (25% 
higher risk among patients with intermediate adherence, 90% higher risk among patients with poor 
adherence) (Kim et al., 2016a).   
In addition, poor adherence to antihypertensive medications contributes to substantial 
healthcare costs and thousands of medical deaths each year (Mennini et al., 2015; Pittman, Tao, 
Chen, & Stettin, 2010; Vrijens, Antoniou, Burnier, de la Sierra, & Volpe, 2017; Will et al., 2016). 
In the United States, HTN patients who demonstrate high levels of adherence to anti-hypertensive 
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medications (>80% adherent) have annual medical costs of nearly $1,000 less than their sub-
optimally adherent (< 60%) peers (Pittman et al., 2010), and research indicates that every dollar 
spent on ensuring adherence to antihypertensive medications saves nearly $4 in subsequent 
medical costs (De Geest & Sabaté, 2003). The cost from potentially preventable hospitalizations 
due to poor antihypertensive adherence totals more than $41 million (Will et al., 2016). Indeed, 
estimates from European countries indicate that increasing rates of adherence among HTN patients 
to just 70% would produce cost savings of more than €332 million (more than $360 million; 
Mennini et al., 2015; Trueman et al., 2010).  
These costs are further magnified with increasing disease severity. Among HTN patients 
who were hospitalized, low antihypertensive adherence was associated with increased costs of 
more than $3,500 over three years, even after adjusting for multiple other factors impacting  
healthcare costs (Dragomir et al., 2010). All-cause mortality has been estimated to be 48% higher 
among non-adherent HTN patients compared to adherent patients, even after adjusting for age, 
gender, cardiovascular risk, and a number of other co-morbidities (Shin et al., 2013). Overall, 
failure to adequately adhere to prescription medications contributes to an estimated $150-$250 
billion in annual healthcare spending in the United States alone (Golay, 2011; Nasseh, Frazee, 
Visaria, Vlahiotis, & Tian, 2012) and accounts for approximately 125,000 medical deaths each 
year (Peterson, Takiya, & Finley, 2003; Viswanathan et al., 2012).  
Poor HTN Adherence in the Elderly. The negative outcomes associated with poor 
adherence are further exacerbated among the elderly. Rates of poor adherence continue to increase 
as patients age, magnifying the risk among older adults (Turner, Hollenbeak, Weiner, Ten Have, 
& Roberts, 2009). Non-adherent elderly patients are approximately two times more likely to be 
hospitalized than age-matched adherent patients (Taylor & Block, 2007; Will et al., 2016), and the 
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association between non-adherence and hospitalization risk increases with age (Chan, Nicklason, 
& Vial, 2001; Col, Fanale, & Kronholm, 1990; Doggrell, 2010; Hughes, 2004). Among the elderly, 
poor adherence is associated with greater disease progression, declines in functional abilities, 
increased risk of coronary and cerebrovascular events (e.g., heart attacks, strokes), and increased 
risk of death (Chowdhury et al., 2013; Gehi et al., 2007; Ho et al., 2006; Horwitz et al., 1990; 
Weitzman et al., 2014; Yang, Chang, Ritchey, & Loustalot, 2017). Indeed, risk for cardiovascular 
events is more than twice as high among elderly patients with low antihypertensive adherence 
compared to those who maintain adherence rates above 80% (Yang et al., 2017). Unsurprisingly, 
given these findings, low adherence to antihypertensive medication has also been linked with 
lower health-related quality of life among older adults (Holt, Muntner, Joyce, Webber, & Krousel-
Wood, 2010).  
The serious health consequences associated with poor HTN medication adherence among 
the elderly has spurred an explosion of research into the numerous biomedical, psychological, 
social, and environmental factors that can act as barriers to optimal adherence (for several recent 
systematic reviews, see: Alghurair, Hughes, Simpson, & Guirguis, 2012; Khatib et al., 2014; van 
der Laan et al., 2017). Among the myriad of potential barriers, cognitive impairment has been 
identified as an important risk factor for poor antihypertensive adherence among older adults (Cho 
et al., 2018; Vinyoles et al., 2008). Adherence is a cognitively complex task and has been found 
to rely on a number of intact neuropsychological processes, including memory, language, 
information processing speed, and fine motor function (Cardenas-Valladolid et al., 2010; Manning 
et al., 2012; Nikolaus et al., 1996; Schutte, 2006; Stilley, Bender, Dunbar-Jacob, Sereika, & Ryan, 
2010; Stoehr et al., 2008; Yap, Thirumoorthy, & Kwan, 2015b).  
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In addition to these lower-level cognitive processes, the complex, multifaceted, and 
sustained nature of long-term adherence suggests that higher-order, top-down processes 
collectively known as executive functioning (EF) may also be important. As such, the potential 
role of EF in adherence to antihypertensive medications is deserving of consideration.  
Executive Functioning 
Although EF has long been characterized as a core neuropsychological domain, a 
consensus definition for the construct has remained elusive (Lezak, Howieson, Bigler, & Tranel, 
2012; Miyake & Friedman, 2012; Suchy, 2009). EF is distinct from general intellectual 
functioning, and is considered to have both a unitary quality and to consist of correlated but 
dissociable cognitive processes, known as executive processes (Friedman et al., 2006, 2008; Lezak 
et al., 2012; Miyake & Friedman, 2012; Miyake et al., 2000; Vaughan & Giovanello, 2010).1 These 
processes are recruited to enable adaptive, effortful, and goal-oriented behaviors (Lezak et al., 
2012). Traditionally associated with the frontal lobes, particularly the prefrontal cortex (PFC) and 
its connections to the rest of the brain (Alvarez & Emory, 2006; Goh, Beason-Held, An, Kraut, & 
Resnick, 2013; Lezak et al., 2012), EF is often conceptualized as influencing the way in which 
behaviors and lower cognitive functions are expressed, rather than the precise nature or content of 
those processes (Lezak et al., 2012; Miyake & Friedman, 2012; Suchy, 2009).  
EF has been found to have a strong genetic component (Bowirrat et al., 2012; Friedman & 
Miyake, 2017; Friedman et al., 2008; Logue & Gould, 2014). Evidence from twin studies suggests 
that individual executive processes are each significantly impacted by genetic influences, both a 
highly heritable common EF factor and additional genetic influences specific to each particular 
                                                 
1 EF research has long been plagued by vague and inconsistent terminology. For the purpose of clarity, in this 
study, the term EF will be used to refer to executive functioning as a broad neuropsychological domain, and the 
higher-order functions that contribute to this ability (e.g., inhibition) will be referred to as executive processes. 
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executive process (Friedman & Miyake, 2017; Friedman et al., 2016, 2008). Importantly, however, 
gene-environment interactions can also significantly impact EF. Socioeconomic factors in early 
childhood have been shown to be particularly important for the development of EF (Diamond, 
2014; Lipina et al., 2013; Raver, Blair, & Willoughby, 2013). Researchers have also emphasized 
that heritability does not preclude mutability or change in these processes over time (Best, 
Nagamatsu, & Liu-Ambrose, 2014; Diamond, 2014; Luszcz, 2010; Miyake & Friedman, 2012; 
Vaughan & Giovanello, 2010).  
EF and Aging. Indeed, declines in EF are well-documented over the course of normal 
aging (Diamond, 2014; Etienne, Marin-Lamellet, & Laurent, 2008; Fjell, Sneve, Grydeland, 
Storsve, & Walhovd, 2016; Luszcz, 2011; Salthouse, 2013). Compared to younger and middle-
aged adults, even healthy older adults show declines in EF across a number of domains, including 
inhibition, set-shifting, working memory, verbal fluency, and abstract thinking (Clark et al., 2009; 
Delis, Kramer, Kaplan, & Holdnack, 2004; Emery, Hale, & Myerson, 2008; Fiore, Borella, 
Mammarella, & De Beni, 2012; Lustig & Jantz, 2015; Wasylyshyn, Verhaeghen, & Sliwinski, 
2011).  
EF declines in aging are believed to stem from age-related vulnerability of the PFC and its 
connections to the rest of the brain. As the brain ages, the PFC becomes increasingly inefficient 
and disconnected, which impedes EF and contributes to cognitive decline (Fjell et al., 2016; Jurado 
& Rosselli, 2007; Park & Reuter-Lorenz, 2009; Rae, Hughes, Anderson, Rowe, & Rowe, 2015; 
Ward, Seri And, & Cavanna, 2013). In a longitudinal study comparing cohorts of younger and 
middle aged adults with a group of older adults, more than 80% of the observed changes in EF 
could be attributed to structural changes in brain connectivity over time (Fjell et al., 2016). Because 
the PFC is more vulnerable to the aging process than many other areas of the brain, EF changes 
  
   13 
typically predate declines in other cognitive functions (Carlson, Xue, Zhou, & Fried, 2009; Jurado 
& Rosselli, 2007), and reductions in EF abilities go beyond age-related declines in more basic 
cognitive processes (Fjell et al., 2016; Royall, Palmer, Chiodo, & Polk, 2004).  
Executive Processes. While many of these aspects of the EF construct and its course over 
the lifespan are broadly accepted, the specific processes that underlie EF remain a matter of debate, 
and numerous models of EF have been proposed (e.g., Baddeley, 1998; Barrett, Tugade, & Engle, 
2004; Damasio, 1995; Delis et al., 2004; Fuster, 2000; Lezak et al., 2012; Miyake et al., 2000; 
Norman & Shallice, 1986; Stuss & Alexander, 2000). Alternative approaches often differ 
dramatically in the number or scope of the processes and abilities integrated under the EF umbrella 
(for a review of more than 15 such models, see Burgess & Simons, 2012). In addition, some 
researchers, including some who study adherence, have adopted atheoretical approaches to EF that 
neglect its multifaceted nature or haphazardly incorporate a “laundry list” of poorly integrated 
concepts (Suchy, 2009).  
In an influential factor analysis, Miyake and colleagues (2000) sought to address this 
concern, identifying three core executive processes: set-shifting, information updating and 
monitoring, and inhibition. Set-shifting concerns the ease with which individuals can switch 
flexibly between different tasks or mental sets, an ability which can also be conceptualized as 
‘mental flexibility.’ Updating and monitoring information relates closely to the construct of 
working memory, and refers specifically to the need to dynamically manipulate, maintain, and/or 
replace mental representations as part of a task. Inhibition refers to one’s ability to intentionally 
suppress automatic or prepotent responses in favor of an alternate response.  
These processes are fairly distinct, but do correlate loosely with one another and with a 
unitary EF construct (Diamond, 2014; Friedman & Miyake, 2017; Miyake & Friedman, 2012; 
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Miyake et al., 2000). Despite substantial variability in models of EF, both in research and clinical 
practice, these three executive processes are widely cited and have broad empirical support. This 
model of EF and its component executive processes have been replicated in diverse samples 
(Fournier-Vicente, Larigauderie, & Gaonac’h, 2008; Friedman et al., 2006, 2008; Ito et al., 2015; 
Rose, Feldman, & Jankowski, 2012; Usai, Viterbori, Traverso, & De Franchis, 2014; Willcutt et 
al., 2001), including samples of older adults (Fisk & Sharp, 2004; Hedden & Yoon, 2006; Hull, 
Martin, Beier, Lane, & Hamilton, 2008; Vaughan & Giovanello, 2010), and have been supported 
by neuroimaging studies (Collette et al., 2005; Lemire-Rodger et al., 2019; Sylvester et al., 2003). 
Based on this growing literature, these three core executive processes have been incorporated into 
broad neuroanatomical, developmental, and behavioral theories of EF (Alvarez & Emory, 2006; 
Diamond, 2014; Hall & Fong, 2013; Hall & Marteau, 2014; Hofmann, Friese, & Wiers, 2008; 
Luszcz, 2010; Salthouse, Atkinson, & Berish, 2003). 
EF in Chronic Disease. A growing body of literature supports a role of EF in health and 
chronic disease (Allan, McMinn, & Daly, 2016; Hall & Fong, 2013, 2015; Hall & Marteau, 2014; 
Moffitt et al., 2011; Williams & Thayer, 2009). EF has been linked to important preventative health 
behaviors, such as exercise and dietary control, as well as health risk behaviors, such as tobacco 
and alcohol use and risky sex behaviors (Allan, Johnston, & Campbell, 2010; Amiaz, Levy, 
Vainiger, Grunhaus, & Zangen, 2009; Best et al., 2014; Brega, Grigsby, Kooken, Hamman, & 
Baxter, 2008; Daly, McMinn, & Allan, 2015; Desouky, 2013; Fernie et al., 2013; Gettens & Gorin, 
2017; Hall, 2012; Hall & Fong, 2015; Hall, Fong, Epp, & Elias, 2008; Huebner, McGarrity, Smith, 
Perry, & Suchy, 2018; Jansen et al., 2013; McAuley et al., 2011; Nestor, McCabe, Jones, Clancy, 
& Garavan, 2011). In one study of older adults, EF was also been shown to be associated with all-
cause mortality over 10 years; this association seemed to be primarily attributable to the incidence 
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of new onset chronic diseases (Hall, Dubin, Crossley, Holmqvist, & D’Arcy, 2009), emphasizing 
EF’s role in chronic disease acquisition in particular.  
Adherence and EF. In conjunction with a growing recognition that EF is important to 
overall health and disease prevention (Hall, Fong, Epp, & Elias, 2008; Hall & Marteau, 2014; 
Moffitt et al., 2011; Williams & Thayer, 2009), research into the role of EF in medication 
adherence has increased substantially over the past ten years. Consistent adherence to medication 
involves complex cognitive and behavioral tasks, including arranging for continuous access to 
medications, understanding prescribed directions, planning and integrating doses into daily 
activity, adjusting and problem-solving for changes to schedules, and monitoring one’s own 
medication-taking behavior to avoid forgetting or double-dosing (Campbell et al., 2012; Insel, 
Morrow, Brewer, & Figueredo, 2006; Stilley et al., 2010). These requirements are further 
compounded when an individual must manage multiple medications and additional medication-
related behaviors (e.g., meals), as is common in HTN (Alghurair et al., 2012; Cooney & Pascuzzi, 
2009; van der Laan et al., 2017). The complexity of these actions would seem to necessitate the 
involvement of both core and higher-order executive processes.  
A growing body of literature indicates that impaired EF is a risk factor for poor medication 
adherence. For example, in studies of people living with HIV, worse EF has been consistently 
linked to poor adherence to anti-retroviral therapies across a number of EF and adherence measures 
(Ettenhofer et al., 2009; Gorman, Foley, Ettenhofer, Hinkin, & Van Gorp, 2009; Hernández 
Huerta, Parro Torres, Madoz Gúrpide, Ochoa Mangado, & Pérez Elias, 2016; Lovejoy & Suhr, 
2009; Panos et al., 2014). Furthermore, impaired EF has been found to interact with other risk 
factors, including age and medication regimen complexity, to increase the likelihood of poor 
adherence among individuals living with HIV (Ettenhofer et al., 2009; Hinkin et al., 2002). 
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Research that has specifically examined mental flexibility has shown consistent associations 
between poorer set-shifting and suboptimal anti-retroviral adherence, even after controlling for a 
number of additional demographic and clinical risk factors (Avants, Margolin, Warburton, 
Hawkins, & Shi, 2001; Hernández Huerta et al., 2016; Solomon & Halkitis, 2008). Based on these 
findings, two systematic reviews concluded that EF deficits are significantly associated with poor 
adherence among patients living with HIV (Gorman et al., 2009; Lovejoy & Suhr, 2009). 
Mental flexibility was also associated with adherence to cholesterol-lowering medication 
in a sample of adults with elevated cholesterol levels (Stilley, Sereika, Muldoon, Ryan, & Dunbar-
Jacob, 2004), underscoring the potential importance of this executive process. Further, among 
patients with Type 2 diabetes, composite EF scores were found to moderate the relationship 
between adherence and prospective memory (Baek, 2014). Only patients with both low EF and 
low prospective memory scores were found to be at risk for poor adherence to diabetes medication; 
the relationship between prospective memory and adherence was not significant when EF was 
uncompromised (Baek, 2014). Deficits in inhibition and set-shifting have also been implicated in 
poor medication adherence for patients with Type 2 diabetes (Rosen et al., 2003; Stilley et al., 
2010). Set-shifting performance among a sample of male Parkinson’s Disease patients was also 
positively associated with estimated adherence (Manning et al., 2012).  
EF & Adherence in Older Adults. Studies of EF and adherence among older adult 
populations, though few in number, have echoed these findings. In an eight-week cohort study of 
participants aged 67 and older, Insel and colleagues (2006) reported that higher baseline EF and 
working memory scores were significantly predictive of better adherence, even after controlling 
for a number of demographic and health risk factors associated with poor adherence. In contrast, 
verbal memory scores were not significantly predictive of adherence (Insel et al., 2006). Similarly, 
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in a large scale study of adults aged 65 and older, baseline performance on a measure of set-shifting 
and mental flexibility was strongly associated with being fully adherent to prescription 
medications, as determined by a nurse’s judgment based on a combination of pill counts, clinical 
markers, and patient-report (Stoehr et al., 2008). While better verbal memory in this sample was 
associated with increased ability to set up a medication schedule, it was not predictive of adherence 
itself (Stoehr et al., 2008). 
Growing evidence suggests that the relationship between EF and medication adherence 
increases as individuals age. In two comparison studies of young versus older patients with HIV, 
EF performance was predictive of adherence among older patients but not among younger patients, 
despite the fact that age-adjusted EF scores did not significantly differ between the two age groups 
(Barclay et al., 2007; Ettenhofer et al., 2009). Similarly, although multiple studies implicate EF in 
medication adherence and successful glycemic control among older samples of Type 2 diabetic 
patients (Munshi, Hayes, Iwata, Lee, & Weinger, 2012; Nguyen et al., 2010; Primožič, Tavčar, 
Avbelj, Dernovšek, & Oblak, 2012; Rosen et al., 2003; Stilley et al., 2010), this relationship is 
attenuated in younger samples (Baek, 2014). 
A Proposed Model of EF and Adherence. These findings seem to indicate an important 
role for EF in adherence to medication in chronic disease. However, while several models have 
been published to date connecting EF and/or specific executive processes to a number of health 
behaviors, including obesity and dietary control, weight loss maintenance, and physical activity 
(Gettens & Gorin, 2017; Hall & Fong, 2015; Hofmann et al., 2008; Jauch-Chara & Oltmanns, 
2014), to date, no such models have applied neuropsychological perspectives of EF to medication 
adherence, and the current lack of an integrated neuropsychological model of adherence has 
impeded the ability to draw more fine-grained conclusions about the precise nature of this 
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relationship. Most studies of EF and medication adherence have used a composite measure of EF, 
and have not reported the associations between adherence and specific executive processes. As a 
result, little is known about whether certain executive processes may be differentially involved in 
specific aspects of successful adherence to medication.  
In order to improve the understanding of how EF impacts medication adherence, this 
relationship can be assessed by applying an empirically-validated model of its component 
processes, such as the model proposed by Miyake and colleagues (2000), to specific behaviors and 
abilities known to be important to sustained medication adherence. While it is likely that age-
related declines in broad EF ability underlie poor adherence to medication to some extent, it is also 
reasonable to expect that specific deficits in executive processes like mental flexibility, working 
memory, and inhibition could result in specific difficulties adhering to medications. A model of 
the potential impact of these executive processes on specific adherence behaviors is presented in 
Figure 1.  
Set-shifting abilities likely play a role in moderating individuals’ ability to sustain 
adherence. Successful adherence requires the ability to adjust medication-taking behaviors to 
changing schedules and new routines (e.g., continuing to follow medication instructions while 
travelling), tasks which would seem to depend on mental flexibility and set-shifting (Campbell et 
al., 2012; Hain, Tappen, Diaz, & Ouslander, 2012). It also seems reasonable that set-shifting would 
contribute to problem-solving related to potential barriers to medication access (e.g., how to get to 
the pharmacy for a refill), as individuals must flexibly consider alternative options and adopt a 
strategy that may not be typical for them (Cronin-Golomb, Corkin, & Growdon, 1994; Star & 
Rittle-Johnson, 2008). Similarly, given the likelihood of changes in prescription regimen in the 
initial stages of HTN treatment (Whelton et al., 2018), mental flexibility plays an important role 
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in individuals’ ability to transition away from their previous medication-taking patterns and shift 
successfully to their new regimen (e.g., switch from taking pills once per day to taking pills twice 
per day). 
Set-Shifting 
Updating and 
Monitoring 
Information 
Inhibition 
 Adjust to schedule changes 
 Problem-solve around 
potential barriers to access 
(e.g., transportation) 
 Adapt to changes in 
medication regimen 
 Transition away from 
previous medication-taking 
habits 
 
 Self-monitor medication-
taking behavior 
 Arrange for continuous access 
to medications 
 Maintain intention to adhere 
over time, distractions 
 Role in prospective memory 
 
 Suppress distraction, 
retrospective interference 
 Implement adherence plans in 
place of more immediately 
rewarding activities 
 Suppress desire to not take 
meds due to inconvenience, 
side effects, etc.  
 
Figure 1. Conceptual model of the potential impact of specific executive processes on behaviors 
supportive of sustained medication adherence. Reciprocal arrows are drawn between executive 
functions to indicate their correlated and interactive relationships. 
Sustained  
Anti-
hypertensive 
Adherence 
Executive Processes        Adherence Behaviors 
    (Miyake et al., 2000) 
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Information updating is a key factor in the ability to monitor one’s own behavior, a crucial 
aspect of medication adherence (Conn et al., 2009; Haynes et al., 2002; Viswanathan et al., 2012). 
Older adults with difficulty updating mental representations might therefore be at greater risk for 
inaccurately assessing whether or not they have already taken their medication, which could 
increase the likelihood that they would then inadvertently deviate from provider instructions. 
Indeed, because self-monitoring can be more challenging with repetitive behaviors, updating 
abilities may be of particular importance in long-term adherence (Clarys, Bugaiska, Tapia, & 
Baudouin, 2009). Research indicates that updating/working memory also plays a role in 
prospective memory, and intact working memory and updating abilities are crucial for executing 
planned activities (Barrett et al., 2004; Basso, Ferrari, & Palladino, 2010; Kliegel, Martin, 
McDaniel, & Einstein, 2002; Kliegel, McDaniel, & Einstein, 2000; McDaniel & Einstein, 2011). 
Without the ability to hold information and intentions in mind while doing other things (e.g., 
pouring a glass of water), and manipulate and update that information as necessary, it would be 
highly challenging to take medications correctly. Keeping track of when medications are running 
out and maintaining the intention to refill a prescription over intervening time and distractions are 
also important to sustained adherence and would also seem to rely on intact updating and 
monitoring abilities (Barrett et al., 2004). 
Inhibition of automatic or conflicting responses also appears to be important for executing 
the intention to take medication as prescribed. Age-related declines in inhibitory control can make 
older adults more susceptible to distraction and retrospective interference (Brock, Brock, & 
Thiedke, 2012; Etienne et al., 2008). For instance, elderly patients must inhibit memories of taking 
their medication on previous days to retain an accurate understanding of whether they have taken 
their medication that day or still need to do so. They must also filter out distractions that can 
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interfere with their ability to carry out adherence behavior in the moment. Inhibition also becomes 
important when choosing to follow-through on the intention to take medication in place of more 
immediately rewarding activities. For example, it may be more immediately rewarding for an 
individual to go home directly after work, rather than stopping at the pharmacy to pick up a 
prescription, and inhibition of these more desirable but ultimately detrimental actions may play a 
critical role in adherence under such circumstances (Hall & Fong, 2013; Hofmann et al., 2008). 
Suppression of such impulses may be even more important and effortful in the face of other barriers 
to adherence, such as unpleasant side effects or negative beliefs about adherence, when the short-
term appeal of avoiding one’s medication could out-weigh the perceived long-term benefits of 
sustained adherence (Gellad, Grenard, & Marcum, 2011; Krousel-Wood et al., 2009; Yap et al., 
2015b).  
These examples provide a framework for considering potential relationships between 
empirically-validated executive processes and specific difficulties in adhering to medication. 
Research guided by such a framework can provide additional insights into the relative 
contributions of each specific executive process to medication adherence, and will allow for a 
fuller understanding of the ways in which poor EF may lead to suboptimal adherence. This is 
particularly true among aging populations, as evidence from developmental neuroscience suggests 
that certain frontal regions are more susceptible to age-related declines than others, and 
neurological aging may not impact all three core executive processes in the same ways (Etienne et 
al., 2008; Raz, Ghisletta, Rodrigue, Kennedy, & Lindenberger, 2010). 
The Present Study 
Given the prevalence of HTN among older adults and the documented need to sustain high 
levels of adherence to avoid serious detrimental health outcomes, exploring relationships between 
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executive processes and adherence among older adults with HTN could shed light on this 
important health behavior. However, despite mounting evidence from other clinical populations 
regarding the association between EF and adherence, research investigating the role of EF in 
adherence to antihypertensive medications remains sparse.  
The current study sought to address this gap in the literature by assessing the relationship 
between EF and adherence to antihypertensive medications among a sample of older adults with 
HTN. We examined the association between individuals’ performance on a number of 
neuropsychological tests of EF, chosen to reflect the specific executive processes of set-shifting, 
updating, and inhibition, or a combination thereof, and the proportion of doses of antihypertensive 
medication participants missed over the following three months, controlling for demographic and 
disease-related covariates, as necessary. We hypothesized that better baseline scores on each 
measure of EF would predict better subsequent adherence to antihypertensive medications over 
the following three-month study period.   
 
Methods 
Participants 
 Participants were recruited to the current project as part of a broader three-year longitudinal 
study investigating the effects of standard versus intensive HTN management on cerebrovascular 
disease and cognitive functioning among the elderly (White et al., 2013). Participants in this 
broader study were randomized to one of two levels of BP control using an urn randomization 
strategy to reduce imbalance between conditions (Schulz & Grimes, 2002). Participants in the 
Standard condition received open-label HTN treatment with a goal of achieving a systolic BP of 
less than 145 mm Hg, as based on standards of care for older adults at the start of the trial (Beckett 
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et al., 2008). In contrast, participants in the Intensive condition received HTN treatment with a 
goal of achieving a systolic BP of less than 130 mm Hg (White et al., 2013). This lower clinical 
BP target was based on previous findings indicating potential functional benefits among the elderly 
with achievement of systolic BPs below 130 mm Hg (White et al., 2011).  
To be eligible for the broader study, participants were required to (1) be age 75 or older; 
(2) have a seated clinic systolic BP greater than 150 mm Hg; (3) have detectable cerebrovascular 
disease, as indicated by more than 0.5% white matter hyperintensities (WMH) on magnetic 
resonance imaging (MRI); and (4) be able to provide informed consent. To be eligible for the 
current study, participants in the broader study were also required to have at least one documented 
instance of returning unused HTN medication in the three-month period following cognitive 
testing.  
Individuals were excluded from the broader study if they had (1) a history of stroke; (2) 
dementia, as indicated by a score of less than 24 out of a possible 30 on the Mini-Mental Status 
Exam (MMSE), a widely used dementia screening tool (Folstein, Folstein, & McHugh, 1975); (3) 
uncontrolled diabetes, as indicated by HbA1c levels greater than 10%; (4) poor kidney function, 
as indicated by estimated glomerular filtration rate (eGFR) below 25 mL/min; (5) active liver 
disease or elevated serum transaminases (more than three times the normal limit); (6) history of a 
major cardiovascular event (e.g., myocardial infarction) or procedure (e.g., cardiac bypass surgery) 
within the past three months; (7) uncompensated congestive heart failure (class III or IV, or 
documented ejection fraction below 30% (American Heart Association, 2013)); (8) chronic atrial 
fibrillation that would interfere with ambulatory BP monitoring; (9) clinically impaired gait, as 
indicated by a score of less than nine out of a possible twelve on the Short Physical Performance 
Battery for gait (Stands, 2000); (10) body mass index (BMI) greater than 45 kg/m2 and/or arm 
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circumference greater 44 cm; (11) medical conditions that limited life expectancy to less than three 
years; or (12) MRI contraindications, such as MRI-incompatible implants or severe claustrophobia 
(White et al., 2013). No additional exclusion criteria were applied to the current study. Due to the 
exploratory nature of the study and the fact that participants were necessarily drawn from a study 
with different statistical objectives, no a priori power analysis was conducted to guide recruitment.  
Sample size for the current study was estimated to be adequate based on similar studies from other 
clinical populations (Ettenhofer, Foley, Castellon, & Hinkin, 2010; Insel et al., 2006; Manning et 
al., 2012; Stilley et al., 2010). 
Procedure 
All neuropsychological testing was administered by a Master’s or post-doctoral level 
clinician under the supervision of a licensed, board-certified neuropsychologist. Testing was 
completed during the course of a longer study visit that included in-clinic BP monitoring and 
consultation with a nurse and the attending cardiologist. Additional procedures incorporated into 
some study visits included mobility assessment, initiation of ambulatory BP monitoring, and/or 
MRI, all of which took place after cognitive testing was complete. Visits took place in the morning, 
between 8am and 11am, and were conducted in the Clinical Research Center at the University of 
Connecticut Health Center (UConn Health) in Farmington, CT. Neuropsychological tests were 
administered individually in a quiet consultation room. All participants completed the tests in the 
same standardized order, with the exception of participants with colorblindness (n = 3), who were 
not administered the color naming or color-word conditions of the Stroop Color Word Test.  
Participants returned for follow-up BP monitoring and medication consultations one, two, 
and three months after baseline cognitive testing, with additional visits as needed to guide HTN 
treatment. All antihypertensive medications were dispensed through the University of Connecticut 
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Health Center Research Pharmacy and were provided free of charge through the study. Participants 
received study medications during their visits. Medication type and dosage were guided by study 
design and the clinical judgment of the study cardiologist, and included the following drug classes: 
dihydropyridine calcium antagonists, angiotensin-converting enzyme (ACE) inhibitors, 
angiotensin receptor blockers, thiazide diuretics, loop diuretics, β-adrenergic blockers, α-
adrenergic blockers, and aldosterone antagonists (White et al., 2013).  
Study staff collected and documented unused medications at subsequent follow-up visits. 
Pill counts of unused medication were conducted at the time of return and recorded in participant 
case records. Unused medications were returned to the UConn Health Research Pharmacy for 
proper disposal. 
The University of Connecticut Health Center’s Internal Review Board approved all study 
procedures and measures. 
Measures 
Demographics. At study entry, participants provided basic demographic information 
including their age, gender, race, ethnicity, highest level of education, and handedness. 
Medication Use. Research staff documented all antihypertensive medications dispensed 
to participants during the course of the study, including medication name, dosage, frequency (e.g., 
twice daily), quantity given, date dispensed, quantity returned, and date returned.   
Medication Adherence. Medication adherence was assessed using the proportion of 
missed doses, as calculated from pill counts, a commonly used objective method for estimating 
adherence (Lam & Fresco, 2015). Rather than relying on patient report, which is prone to reporting 
bias and adherence overestimates, particularly among the elderly (Lehmann et al., 2014; Soubelet 
& Salthouse, 2011; Williams, Amico, Bova, & Womack, 2013), pill counts are based on the 
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number of pills remaining after a given time period, compared to the number of pills the patient 
was prescribed.  
For the purposes of this study, the proportion of missed doses over the study period was 
calculated using the following methodology: (1) We calculated the number of doses of a given 
medication required to cover the interval between when pills were dispersed and when they were 
returned, based on the number of days and the number of doses taken per day. (2) We then 
calculated the number of pills needed to cover all required doses between the date of dispersal and 
the date extra pills were returned, based on the number of doses and the number of pills required 
per dose. (3) We subtracted the number of pills needed over the specified time frame from the 
number of pills dispensed over that period, indicating how many “extra” pills had been dispensed 
to the participant. (4) We subtracted the number of “extra” pills from the number of total pills 
returned, to yield the number of missed doses. This corrected for the tendency to refill prescriptions 
before running out and helped avoid overestimation of the number of missed doses (Lam & Fresco, 
2015). (5) The same methodology was repeated for each medication that was dispensed and 
returned within the three-month period following cognitive testing. Medications that were 
dispensed within three months of cognitive testing but were returned outside that time frame were 
not included in analyses. (6) The number of missed doses for each medication were summed to 
yield a total number of missed doses for the participant. (7) The number of required doses for each 
medication were summed to yield a total number of intended doses for the participant. (8) The 
number of missed doses was divided by the number of intended doses, then multiplied by 100%, 
resulting in a percentage of what percentage of their prescribed doses each participant had missed 
over the study period.  
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Return data was missing for one or more prescriptions dispensed in the three months post-
testing for multiple participants. We took a conservative approach to this missing data, and 
assumed the best-case scenario – perfect adherence (no missing doses) for that medication, to avoid 
artificially inflating the participants’ missed doses. Thus, the total number of missed doses for each 
participant was based only on confirmed pill counts and was not interpolated from missing data. 
Cardiovascular Variables. Baseline cardiovascular risk factors were assessed as possible 
covariates, given that illness severity can impact subsequent adherence to antihypertensive 
medications (Chapman, Petrilla, Benner, Schwartz, & Tang, 2008; Dimatteo, Haskard, & 
Williams, 2007; Kamran, Sadeghieh Ahari, Biria, Malepour, & Heydari, 2014; Spilker, 2006). 
Blood Pressure & Heart Rate. Following upon earlier work indicating that average daily 
BP, as measured by 24-hour monitoring, is a more sensitive indicator of cerebrovascular disease 
progression and functional decline in the elderly (White et al., 2011), systolic BP was assessed via 
24-hour ambulatory BP monitoring for all participants over the course of the study. Average daily 
systolic and diastolic BP and heart rate were based on 80 readings over 24 hours, taken every 15 
minutes between 6am and 10pm, and every 30 minutes between 10pm and 6am. Ambulatory BP 
and heart rate monitoring were conducted using the Oscar II BP device (Suntech Medical 
Instruments). 
Cholesterol. Total cholesterol, high-density lipoprotein (HDL), and low-density 
lipoprotein (LDL) cholesterol were assessed via standard blood draw and laboratory testing 
conducted by the study nurse at baseline.  
Body Mass Index. Elevated BMI has been associated with increased cardiovascular and 
cerebrovascular risk (MacMahon et al., 2009) and has been shown to be related to both medication 
adherence and EF in certain populations of older adults (Gunstad et al., 2007; Holt et al., 2013). 
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As a result, participants’ BMIs were also calculated as potential covariates. The study nurse 
measured each participant’s height (without shoes) and weight (clothed, without shoes) at baseline. 
BMI was calculated as weight in kilograms divided by the square of height in meters. BMI was 
then categorized to reflect underweight (less than 18.5), normal weight (18.5 to 24.9), overweight 
(25 to 29.9), obese (30 or more; Centers for Disease Control and Prevention [CDC], 2019). 
Cerebrovascular Variables. Cerebrovascular risk, as measured by white matter damage, 
was also assessed as a possible covariate, given well-established links between white matter, 
cognitive functioning, and EF among older adults (Dey, Stamenova, Turner, Black, & Levine, 
2016; Fjell et al., 2016; Insel, Reminger, & Hsiao, 2008; Venkatraman et al., 2010).  
MRI neuroimaging was conducted using 1.5-T Siemens Avanto scanner (Erlangen, 
Germany) located on-site at UConn Health. White matter damage was quantified based on areas 
of hyperintensity on T2-weighted three-dimensional fast spin-echo. Imaging analyses were 
performed using the FreeSurfer application (FreeSurfer, 2013) and Matlab (MathWorks, Inc., 
2010) to segment hyperintensitites and calculate the proportion of WMH based on intracranial 
cavity (ICC) volume (Moscufo et al., 2012; White et al., 2013). 
Depression. Because depressive symptoms can impact EF and vascular health in the 
elderly (Baldwin et al., 2004; Steffens & Potter, 2008; Steffens et al., 2004; Taylor, Aizenstein, & 
Alexopoulos, 2013), depression was also assessed as a possible covariate. Participants completed 
the Geriatric Depression Scale (GDS; Yesavage et al., 1982). The GDS consists of thirty yes/no 
questions regarding the presence of common depressive symptoms among older adults; each 
“depressive” answer is scored as one point, and points are summed to yield a total score. Items 
include, “Do you feel your life is empty?” (response of ‘yes’ is “depressive”) and “Are you in good 
spirits most of the time?” (response of ‘no’ is “depressive”). Scores greater than nine indicate mild 
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depression, while scores greater than twenty indicate severe depression. The GDS also assesses 
for the presence of cognitive problems that can be particularly prevalent among depressed elderly, 
including trouble concentrating, memory complaints, and difficulty making decisions (Steffens & 
Potter, 2008; Steffens et al., 2004). These items contribute to the total GDS score. The GDS is a 
widely used and well-validated measure of depressive symptoms among the elderly, and has been 
used in large-scale studies of hypertension in older adults (Brink, Yesevage, & Lum, 2013; 
Greenberg, 2012; Peters et al., 2010).  
Alcohol Use. EF and medication adherence can also be impacted by alcohol use problems 
(Bryson et al., 2008; Irvin et al., 2012). The ten-item Alcohol Use Disorders Identification Test 
(AUDIT; Saunders, Aasland, Babor, De La Fuente, & Grant, 1993) assessed for alcohol 
dependence and problematic alcohol use. Participants self-reported their drinking behaviors (e.g., 
“How often do you have a drink containing alcohol?”, “How often do you have six or more drinks 
on one occasion?”), as well as any alcohol-related functional impairment (e.g., “How often in the 
last year have you failed to do what was normally expected of you because of drinking?”). 
Questions were anchored on a five-point Likert scale, with responses for most questions ranging 
from “never” to “daily or almost daily.” The psychometric properties of the AUDIT are favorable, 
with a high degree of internal consistency, and it has been shown to be useful in studies of older 
adults (Aalto, Alho, Halme, & Seppä, 2011; Draper et al., 2015; Reinert & Allen, 2007).  
 Neuropsychological Variables. Participants completed a number of baseline tests of 
neuropsychological functioning.   
 Estimated Cognitive Functioning. Tests of specific neuropsychological functions, such as 
EF, are best understood in the context of an individual’s general cognitive abilities (Lezak et al., 
2012). For instance, EF scores in the low average range might be expected in an individual who 
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also falls in the low average range intellectually, and would not likely be considered a cause for 
clinical concern. In contrast, for an individual with high average premorbid intelligence, EF scores 
in the same low average range could indicate a relative weakness in their cognitive profile or a 
possible decline in EF due to clinically-relevant neurological processes. Overall cognitive ability 
has also been shown to be important in medication adherence (Deary et al., 2009; Hayes, Larimer, 
Adami, & Kaye, 2009; Patton et al., 2012; Wallin et al., 2015; Yap, Thirumoorthy, & Kwan, 
2015a), making it a potentially relevant covariate for the current study. 
As such, individuals’ overall cognitive functioning was estimated using the Wechsler Test 
of Adult Reading (WTAR), a widely used measure of premorbid intellectual functioning (Ganguli 
et al., 2014; Lezak et al., 2012; Ritchie et al., 2016; Voineskos et al., 2012). The WTAR consists 
of a list of 50 phonetically irregular words of increasing difficulty. Participants read each word 
aloud; correct pronunciations receives a score of one point, for a possible total score of up to 50 
points. Because the target words cannot be pronounced correctly based solely on standard English 
phonology, the test serves as a measure verbal knowledge of English and vocabulary recognition 
(Wechsler, 2001). These cognitive abilities have been found to correlate most highly with overall 
intelligence and are broadly resilient to neurological injury or disease (De Oliveira, Nitrini, 
Yassuda, & Brucki, 2014; Green et al., 2008).  
Raw scores were converted to standard scores to correct for participant age (Wechsler, 
2001). Standard scores have a mean of 100 and a standard deviation of 15. Standard scores on the 
WTAR were then combined with additional demographic variables (gender, race/ethnicity, and 
years of education) to estimate participants’ premorbid full-scale IQ (FSIQ; Wechsler, 2001). 
Combining demographic characteristics with word recognition tasks like the WTAR has been 
shown to improve FSIQ estimates among older adults (Bright & van der Linde, 2018). The WTAR 
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has good psychometric properties and has been widely used both clinically and for research among 
older adults (Bright & van der Linde, 2018; De Oliveira et al., 2014; Ganguli et al., 2014; Lezak 
et al., 2012; Ritchie et al., 2016; Voineskos et al., 2012, Wechsler, 2001). 
Executive Functioning. Participants completed a number of neuropsychological tests of 
EF, including the Trail Making Test, Part B (Trails B), the Wechsler Adult Intelligence Scales-
Fourth Edition (WAIS-IV) Digit Span Backward (Digits Backward) task, the Stroop Color-Word 
Test (Stroop), and two verbal fluency tasks, phonemic/letter fluency and semantic/category 
fluency. Participants also completed the Trail Making Test, Part A (Trails A, administered with 
Trails B) and WAIS-IV Digit Span Forward (Digits Forward, administered with Digits Backward) 
tasks. Although not direct tests of EF, these supplemental tests were administered to allow for 
possible secondary analyses to better isolate specific executive processes. Raw scores on these 
tests were converted to either T-scores (Trails A and B, Stroop, verbal fluency; Golden, 1978; 
Heaton, Miller, Taylor, & Grant, 2004) or scaled scores (Digits Forward and Backward; Wechsler, 
2008) to adjust for demographics such as age, gender, and education. T-scores have a mean of 50 
and a standard deviation of 10. Scaled scores have a mean of 10 and a standard deviation of 3.  
Trail Making Test, Parts A & B. Participants completed Trails A and B (Reitan & Wolfson, 
1985). In the Trails A condition, participants were required to rapidly connect numbered circles in 
chronological order, 1 to 25. Performance was timed and any errors were immediately corrected, 
counting against the participant’s time. Raw completion time scores were then converted into T-
scores (Heaton, Miller, Taylor, & Grant, 2004; Reitan & Wolfson, 1985). Trails A is a widely used 
measure of psychomotor processing speed and is often used in conjunction with Trails B to 
differentiate between overall speed (Trails A) and mental set-shifting abilities (Trails B) 
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(Arbuthnott & Frank, 2000; Lezak et al., 2012; Misdraji & Gass, 2010; Renfrow-Santiso, 2010; 
Salthouse, 2011). 
To that end, participants also completed Trails B, a widely used test of mental flexibility 
that required individuals to alternately shift between sequencing numbers and letters (Reitan & 
Wolfson, 1985). Performance was evaluated based on the time required to complete the task, 
capturing the speed with which participants could accurately shift between mental sets (Lezak et 
al., 2012). If a participant was unable to complete the task within the five-minute time limit, the 
task was discontinued and the participant was assigned a score of 300 seconds (Reitan & Wolfson, 
1985). Lower raw scores indicated faster performance and corresponded to higher T-scores and 
better performance. Trails B is a well-validated measure of mental flexibility and set-shifting 
(Arbuthnott & Frank, 2000; De Oliveira-Souza et al., 2000; Sánchez-Cubillo et al., 2009), and has 
been shown to be sensitive to declines in these abilities among older adults (Perry et al., 2009; 
Salthouse et al., 2000; van den Berg, Kloppenborg, Kessels, Kappelle, & Biessels, 2009; Van der 
Elst, Van Boxtel, Van Breukelen, & Jolles, 2008).  
WAIS-IV Digit Span Forward & Backward. Participants completed the Digit Span Forward 
and Backward tasks from the WAIS-IV Digit Span subtest (Wechsler, 2008). These tests required 
them to repeat increasingly long sequences of numbers, either verbatim or in reverse order, 
respectively. Performance was evaluated based on the number of sequences participants were able 
to repeat/reverse correctly. The task was discontinued when the participants failed to accurately 
repeat/reverse two sequences of the same length. The Digits Forward task is a test of auditory 
attention, as individuals must attend to the sequence of numbers closely to repeat it correctly (Bopp 
& Verhaeghen, 2005; Hale, Hoeppner, & Fiorello, 2002; Woods et al., 2011). Though not a 
measure of EF in itself, it is often used in conjunction with the Digits Backward task to draw a 
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comparison between basic attention and working memory (Bopp & Verhaeghen, 2005; LaBelle, 
Lee, & Miller, 2017; Lezak et al., 2012).   
The Digits Backward task is a widely used measure of information updating and working 
memory, as individuals must hold auditory information in mind and manipulate that information 
to reverse the digits accurately. It has been shown to have high construct validity and reliability 
(Conway et al., 2005; Lefebvre, Marchand, Eskes, & Connolly, 2005; Wechsler, 1997). Both the 
Digits Forward and Backward tasks have been widely used in studies of older adults, including 
studies of medication adherence (Dobbs & Rule, 1989; El-Missiry et al., 2015; Klepin et al., 2014; 
Rosen et al., 2003; Steffens et al., 2004; van den Berg et al., 2009; Waldrop-Valverde et al., 2006). 
Stroop Color Word Test. Participants also completed the Stroop Color Word Test (Stroop; 
Golden, 1978). Another commonly used test of EF, the Stroop test required participants to name 
the ink colors of incongruent color words (e.g., responding “red” to the word blue written in red 
ink) (Golden, 1978; Lezak et al., 2012). The number of correct responses in this paradigm was 
compared to the number of correct responses on more basic tasks (i.e., reading color words and 
naming colors) to provide an interference score. Negative raw interference scores indicated greater 
interference and worse EF performance, and corresponded to lower T-scores (Golden, 1978; 
MacLeod, 1991). The task captures participants’ ability to suppress prepotent responses (i.e., 
reading the word) in favor of a more unusual response (i.e., naming the incongruent ink color). 
The Stroop task is a well-validated measure of inhibition and mental control (Diamond, 2014; 
MacLeod, 1991; Van der Elst et al., 2008; Van Der Elst, Van Boxtel, Van Breukelen, & Jolles, 
2006), and has been shown to be sensitive to declines in inhibitory control among older adults and 
patients with HTN (Jacobs et al., 2013; Uiterwijk et al., 2016; Van Der Elst et al., 2006). 
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Verbal Fluency. Participants also completed two verbal fluency tasks: phonemic/letter 
fluency and semantic/category fluency. For phonemic fluency, participants generated as many 
words as possible from three letters (F, A, and S), with a 60-second time limit for each letter 
(Benton & Hamsher, 1983). The number of words generated for each letter were summed to 
provide a total phonemic fluency score. For semantic fluency, participants generated words from 
a category (Animals) within the same time limit. For each condition, higher word totals indicated 
greater verbal generativity and corresponded to higher T-scores (Benton, 1968; Lezak et al., 2012). 
Although phonemic fluency has been more consistently associated with EF than semantic fluency, 
both tasks rely on a combination of broad EF and executive processes to develop and initiate an 
initial retrieval strategy, self-monitor for errors, and shift between retrieval strategies (Baldo & 
Shimamura, 1998; Diamond, 2014; Shao, Janse, Visser, & Meyer, 2014; Troyer, Moscovitch, & 
Winocur, 1997). Though they do not correspond to a single specific executive process, verbal 
fluency tasks have been widely used as a measure of EF among older adults and were included to 
reflect higher-level tasks dependent upon multiple executive processes (Clark et al., 2012; Klepin 
et al., 2014; Luszcz, 2010; Van Petten et al., 2004; Watson et al., 2010).  
Data Management and Analyses 
 Data from the broader study was stored in multiple de-identified databases during the 
course of the study to maintain blindness to study condition (i.e., neuropsychological data was 
stored separately from blood pressure data and the medication log). As a result, prior to analysis, 
data was consolidated and extracted into a single database containing all relevant variables. Data 
was then cleaned for consistency and checked for computational errors.  
All analyses were conducted using SPSS Statistics software package, version 24.0. 
Frequency and descriptive analyses were completed to assess the distribution of study variables 
  
   35 
and describe the sample. Descriptive statistics were generated for demographic characteristics, 
medication usage across the study, and clinical variables. For the purpose of describing daily 
participant medication usage, prescribed doses for each participant were weighted to account for 
changes in regimen for some individuals over the course of the study. For instance, if a participant 
was prescribed one dose per day for the first 30 days of the study, then was increased to two doses 
per day for the remaining 60 days, their weighted number of doses per day would be 1.6667. The 
average number of doses per day across participants was then calculated based on weighted values. 
Identification of Covariates. Because the outcome of interest – percentage of missed 
doses – was based on count data, it was not expected to be normally distributed (Coxe, West, & 
Aiken, 2009). Subsequent analyses confirmed that, as expected, the adherence data was non-
normal and positively skewed. As such, non-parametric tests were employed for identifying 
possible covariates. Spearman’s rank correlation coefficients were calculated to assess the 
relationships between percentage of missed doses and continuous demographic and clinical 
variables (e.g., age, number of prescribed doses per day, 24-hour BP, GDS scores, etc.). Mann 
Whitney U tests were used to assess for differences in adherence across categorical variables with 
two levels (e.g., gender, handedness, yes/no change in medication regimen), and Kruskal-Wallis 
H tests were used to assess for adherence differences across categorical variables with more than 
two levels (e.g., race/ethnicity, BMI category). It was intended that demographic, medication use, 
and clinical factors found to be significantly associated with percentage of missed doses would 
then be retained in subsequent regression analyses. 
Calculating EF. Composite EF scores were calculated by summing the z-scores of the five 
individual EF tests. Z-scores have a mean of 0 and a standard deviation of 1. Z-scores for each test 
were calculated from raw scores to avoid re-centering variables that had already been normed 
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(Song, Lin, Ward, & Fine, 2013). This method provides scores that are centered specific to the 
sample (rather than broad normative data) and allowed for examination of whether higher EF was 
associated with better adherence within the same sample, even compared to other individuals who 
might also have higher than average EF (Song et al., 2013). 
Predicting Adherence. The aim of the current study was to explore the relationship 
between EF and the percentage of missed doses of antihypertensive medication among this sample 
of older adults with HTN over the 3-month study period. It was hypothesized that each measure 
of EF (Trails B, Digits Backward, Stroop, and both verbal fluency measures) would be 
significantly associated with adherence and that individuals with better EF performance would 
miss a smaller proportion of their medication doses over time. To assess this aim, a series of 
negative binomial regressions was conducted predicting the percentage of missed doses based on 
performance on each of the neuropsychological measures of EF, incorporating any necessary 
covariates. Negative binomial regressions are adapted from Poisson regressions for modelling 
count data, but also allow for over-dispersed data, as was the case for our outcome of interest 
(Coxe et al., 2009). Because negative binomial regressions model non-negative integers (Coxe et 
al., 2009), percentage of missed doses for each participant was rounded to the nearest whole 
number. Residual analyses were conducted for each regression model to assess for outliers and 
confirm assumptions of conditional normality, homoscedasticity, and independence of residuals. 
 
Results 
Demographic Characteristics 
 Participant demographics are summarized in Table 1. At baseline, participants (n = 76) 
ranged in age from 75 to 93, with a mean age of 81.51 years (SD = 4.48). The sample was well-
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balanced with respect to gender; 40 participants (52.6%) identified as male and 36 participants 
(47.4%) identified as female. The majority of participants identified their race as White or 
Caucasian (n = 65; 85.5%) and 9.2% identified as Black or African American (n = 6). 5.3% of the 
sample identified as Hispanic or Latino/a (n = 4), and 1.3% identified as Asian or Asian American 
(n = 1). Most participants reported being predominantly right-handed (n = 69; 90.8%), while the 
remainder reported being predominantly left-handed (n = 7; 9.2%). No participants reported being 
ambidextrous.  
 The sample was relatively well-educated with 79% of participants (n = 60) reporting some 
college education or more. Years of education ranged from 6 to 20 years. Specifically, 3.9% 
reported less than nine years of education (n = 3), 2.6% reported some level of high school 
education (between 9 and 11 years of schooling; n = 2); 14.5% reported high school graduate or 
GED (12 years of schooling; n = 11); 19.7% reported some college and/or an Associate’s degree 
(13-15 years of schooling; n = 15); 28.9% reported completing a Bachelor’s degree (n = 22); and 
30.3% reported graduate level education (more than 16 years of schooling; n = 23). On average, 
participants reported 15.22 years of education (SD = 3.04). Modal years of education was 16, 
equivalent to a Bachelor’s degree.  
Participants were well-balanced in terms of their condition in the broader study; 37 
participants in the current study had been randomized to the standard BP control condition 
(48.68%), while 39 had been assigned to the intensive BP control condition (51.32%).  Participants 
in the current study did not significantly differ from the broader study sample in terms of 
demographic, BP, or neuropsychological characteristics (see Appendix 1). Participants in the 
current study did report slightly higher levels of depressive symptoms (M = 4.84, SD = 4.09), as 
measured by GDS, compared to those individuals who were excluded because they did not have 
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documented instances of returning medications in the three-month period following cognitive 
testing (M = 3.76, SD = 3.63). Although this difference was statistically significant (t (186) = -
2.071, p = 0.040), the means of both groups fell within the normal range for the GDS and do not 
reflect a clinically important difference (Yesavage et al., 1982).  
Medication Usage 
Participant medication usage is presented in Table 2. Over the course of the study, 
participants were prescribed an average of 2.62 doses of antihypertensive medications per day (SD 
= 1.36; calculated from weighted scores as described above). The number of daily antihypertensive 
doses ranged from one dose per day to seven doses per day.  
The majority of participants experienced a change in their antihypertensive medication 
regimen over the course of the study period (n = 50; 65.8%). These regimen changes were most 
commonly dosage adjustments (e.g., increase from 5mg dose to 10mg dose), as was the case for 
31 participants (40.8%), and/or the introduction of a new, additional medication (n = 22; 28.9%). 
Other antihypertensive regimen changes included removal of a medication (n = 7; 9.2%), a switch 
in medication (n = 5; 6.6%), and/or changes in frequency (e.g., increase from once daily to twice 
daily) (n = 4; 5.3%). 19 participants (25.0%) experienced some combination of these changes. 
The maximum number of different antihypertensive medications prescribed to a given 
participant at one time during the course of the study ranged from one to five. Across participants, 
the maximum number of medications prescribed at one time averaged 2.47 (SD = 0.98). The modal 
number of HTN medications prescribed to a participant at one time was two (n = 34; 44.7% of 
participants). An additional 13.2% of participants were prescribed just one medication each day (n 
= 10), 32.9% were prescribed as many as three (n = 21), 10.5% were prescribed as many as four 
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(n = 8), and 3.9% were prescribed as many as five different daily antihypertensive medications (n 
= 3). 
 The most frequently prescribed medication among participants was amlodipine, which was 
prescribed to 55 participants (72.4%). Amlodipine (also called Norvasc) is a calcium channel 
blocker. 35 participants (46.1%) were prescribed losartan (also called Cozaar), an angiotensin-II 
receptor antagonist. 32 participants (42.1%) were prescribed lisinopril. Lisinopril is an ACE 
inhibitor. Hydrochlorothiazide, a thiazide diuretic medication, was prescribed to 26 participants 
(34.2%). 24 participants (31.6%) were prescribed metoprolol, a beta blocker. Doxazosin, an 1-
selective adrenergic blocker, was prescribed to 11 participants (14.5%). Less commonly prescribed 
were furosemide, a loop diuretic medication (n = 6; 7.9%) and spironolactone, an aldosterone 
receptor antagonist (n = 5; 6.6%). All of the medications were taken orally, in pill form. Additional 
information regarding common side effects and medication instructions (American Society of 
Health-System Pharmacists, 2019) is presented in Appendix 2.  
Clinical Characteristics 
 Cardiovascular Factors. Baseline clinical characteristics of the sample are presented in 
Table 3. Average systolic BP across the sample was 151.54 mm Hg (SD = 12.52), as measured by 
24-hour BP monitoring, consistent with HTN. Average diastolic BP was 74.83 mm Hg (SD = 
9.00). Heart rate, also measured by 24-hour monitoring, averaged 67.53 beats per minute across 
the sample (SD = 8.50).  
 Mean total cholesterol across the sample was 179.83 mg/dL (SD = 41.76), broadly 
consistent with healthy blood cholesterol levels (National Heart, Lung & Blood Institute [NHLBI], 
2019). Total cholesterol levels ranged from 113 to 211 mg/dL. HDL cholesterol levels ranged from 
27 to 104 mg/dL, with an average of 55.16 mg/dL (SD = 15.86). Average HDL levels across the 
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sample were also consistent with recommended guidelines (NHLBI, 2019). LDL cholesterol levels 
ranged from 27 to 191 mg/dL, with an average 103.95 mg/dL (SD = 32.81). This is slightly above 
the recommended guidelines (recommended < 100 mg/dL; NHLBI, 2019), and indicate that our 
sample had slightly elevated serum LDL levels overall. 
Average BMI in our sample was 27.76 mg/m2 (SD = 5.02), which falls in the overweight 
category overall (CDC, 2019). Participants’ BMIs ranged from 19 (normal weight range) to 41 
(obese range). 28.9% of participants (n = 22) had a BMI in the normal weight range (18.5 – 24.9), 
32.9% (n = 25) had a BMI in the overweight range (25 – 29.9), and 38.2% (n = 29) had a BMI in 
the obese range (30+; CDC, 2019). No participants fell in the underweight range (BMI < 18.5). 
 Cerebrovascular Factors. Due to inclusion criteria for the broader study, all participants 
had detectable cerebrovascular disease, as indicated by more than 0.5% WMH on MRI. Average 
level of WMH across the sample was 1.49% of the intracranial cavity (SD = 1.15; range = 0.523-
6.262). 
Depression. Participants reported low levels of depressive symptoms overall (M = 4.84, 
SD = 4.09), and a majority scored in the non-depressed range on the GDS (n = 64; 84.2%). 14.5% 
of participants reported symptoms consistent with mild depression (n = 11). No participants 
reported depressive symptoms in the moderate or severe range. GDS data was missing for one 
participant (1.3%).   
Alcohol Use. Participants reported low levels of alcohol use and alcohol-related problems 
on average (M = 2.56, SD = 2.73), and the large majority (n = 72; 94.7%) scored below the clinical 
cut-off for potential alcohol abuse on the AUDIT. Four participants (5.3%) scored above clinical 
thresholds, indicating potentially hazardous or harmful alcohol use. 
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Neuropsychological Functioning 
Descriptive statistics for neuropsychological tests are presented in Table 4. As noted above, 
raw scores for these tests were converted to either standard scores, T-scores, or scaled scores to 
adjust for demographics. As described above, standard scores have a mean of 100 and standard 
deviation of 15. T-scores have a mean of 50 and a standard deviation of 10. Scaled scores have a 
mean of 10 and a standard deviation of 3. Qualitative classification of test performance was based 
on Wechsler labels for the WTAR, WTAR-estimated FSIQ, and WAIS-IV Digit Span test 
(Wechsler, 2008). Heaton descriptors were used for Trails A and B, the Stroop, and both verbal 
fluency tasks (Heaton et al., 2004).  
Estimated Cognitive Ability. Raw WTAR scores were converted to standard scores to 
account for differences in participant age (Wechsler, 2001). Standard scores on the WTAR ranged 
from 69 (extremely low range) to 128 (superior range). On average, participants scored in the high 
average range, with a mean WTAR standard score of 113.76 (SD = 14.17). This was broadly 
consistent with the high overall level of education among the sample.  
Overall premorbid cognitive ability was estimated based on WTAR performance and 
demographic factors, including gender, race/ethnicity, and years of education (Wechsler, 2001). 
After adjusting for these additional variables, estimated FSIQ ranged from 77 (borderline range) 
to 126 (superior range). Average premorbid cognitive functioning was also in the high average 
range, with a mean estimated FSIQ of 112.32 (SD = 12.12).  
Executive Functioning.  
Composite EF. Composite scores based on all five tests of EF were calculated by summing 
z-scores, as described above. Composite EF scores ranged from -8.92 to 6.21, with a mean of 0.36 
(SD = 3.36). A correlation matrix of neuropsychological test results is presented in Appendix 3. 
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Trail Making Test, Parts A & B. Raw scores for Trails A and B were converted to T-scores 
(Heaton et al., 2004), adjusting for age, gender, race, and education. For Trails A, participants 
scored in the average range overall, with a mean T-score of 53.93 (SD = 8.21). T-scores for Trails 
A ranged from 16 (severely impaired range) to 65 (superior range).  
For Trails B, participants also scored in the average range overall, with a mean T-score of 
50.94 (SD = 10.64). Similarly, T-scores for Trails B ranged from 14 (severely impaired range) to 
63 (high average/superior range).    
WAIS-IV Digits Forward & Backward. Raw scores for the WAIS-IV Digit Span task were 
converted to scaled scores, adjusting for age (Wechsler, 2008). Overall, participants scored in the 
average range on Digits Forward, with a mean scaled score of 9.51 (SD = 2.79). Scaled scores for 
Digits Forward ranged from 6 (borderline range) to 19 (very superior range).  
Participants also scored in the average range overall on Digits Backward, with a mean 
scaled score of 9.76 (SD = 2.76). Scaled scores for Digits Backward ranged from 5 (borderline 
range) to 19 (very superior range). 
Stroop Color Word Test. Raw scores for the Stroop test were converted to T-scores 
(Golden, 1978), adjusting for age. In the word-reading condition, participants scored in the low 
average range overall, with a mean T-score of 43.33 (SD = 8.47. Word-reading T-scores ranged 
from 27 (moderately impaired range) to 66 (superior range). For the color-naming condition, 
participants achieved an average T-score of 40.78 (low average range; SD = 7.18). Color-naming 
T-scores ranged from 21 (moderately/severely impaired) to 58 (high average range). On the 
incongruous color-word task, participants scored in average range overall, and achieved an average 
T-score of 47.31 (SD = 9.07). Performance ranged from severely impaired (T = 20) to superior (T 
= 69).  
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Interference scores for each participant were calculated from their raw scores on the three 
conditions, then converted to T-scores. Overall, participants’ interference scores fell in the average 
range, with a mean T-score of 53.78 (SD = 6.41). Interference T-scores ranged from 
mildly/moderately impaired (T = 32) to superior/very superior (T = 73). 
Verbal Fluency. Raw scores for both verbal fluency tasks were converted to T-scores 
(Heaton et al., 2004). For phonemic/letter fluency (FAS), participants scored in the average range 
overall, with a mean T-score of 47.57 (SD = 10.64). Phonemic fluency performance ranged from 
the moderately/severely impaired range (T = 24) to the superior/very superior range (T = 74) across 
the sample.  
Similarly, for semantic/category fluency (Animals), mean performance across participants 
was in the average range (T = 50.38; SD = 11.49), and ranged from severely impaired (T = 17) to 
very superior (T = 77).  
Medication Adherence 
 A breakdown of medication adherence is presented in Table 5. Overall, participants were 
largely adherent to their study medications. On average, participants missed 6.32% of their doses 
of antihypertensive medication in the three months following cognitive testing (SD = 10.35). As 
predicted, the percent of doses missed was highly skewed. The median value of percent of doses 
missed was 2.01, indicating that half of the sample missed 2% or less of their doses.  
 A sizeable subset of participants (n = 27; 35.5%) did not miss any of their prescribed 
antihypertensive doses. An additional 19 participants (25.0%) missed between 0.1 and 5% of their 
doses. 15 participants (19.7%) missed between 5.1 and 10% of their doses. 8 individuals (10.5%) 
missed between 10.1 and 15% of their doses. 3 (4.0%) missed between 15.1 and 30% of doses, 
and only 4 (5.3%) missed more than 30% of their doses. 
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 Demographic Risk Factors. Relationships between adherence and demographic variables 
were assessed using Spearman’s rank correlation coefficients, Mann-Whitney U tests, and 
Kruskal-Wallis H tests, as appropriate. Participant age was not significantly correlated with 
percentage of missed doses ( = 0.101; p = n.s.). Similarly, medication adherence did not 
significantly differ by gender (U = 557.50; p = n.s.), racial/ethnic identity (2(3) = 2.402; p = n.s.), 
years of education ( = -0.155; p = n.s.), or handedness (U = 210.00; p = n.s.). Medication 
adherence also did not significantly vary by participants’ group assignment in the broader study; 
participants in both the standard and intensive BP control conditions demonstrated similar levels 
of medication adherence (U = 719.50; p = n.s.). 
 Medication-Related Risk Factors. Relationships between adherence and medication-
related risk factors were assessed with Spearman’s rank correlation coefficients and Mann-
Whitney U tests. The number of doses of antihypertensive medication per day was not significantly 
correlated with the percentage of doses participants missed ( = -0.146; p = n.s.). The number of 
different medications a participant was prescribed at one time was also not significantly associated 
with medication adherence ( = -0.105; p = n.s.). The percentage of missed doses did not vary 
between those individuals who experienced a change in their medication compared to those 
individuals whose prescription regimen remained the same over the course of the study (U = 
612.00; p = n.s.). 
Clinical Risk Factors. Relationships between percent of doses missed and clinical 
variables were also assessed using Spearman’s rank correlation coefficients, Mann-Whitney U 
tests, and Kruskal-Wallis H tests.  
Cardiovascular Factors. Correlation coefficients for cardiovascular variables are reported 
in Table 6. There were no significant associations between antihypertensive adherence and 24-
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hour systolic or diastolic BP ( = -0.004; p = n.s. and  = 0.010; p = n.s., respectively). Similarly, 
medication adherence was not correlated with 24-hour heart rate ( = 0.021; p = n.s.), total ( = 
0.089; p = n.s.), HDL ( = 0.191; p = n.s.), or LDL cholesterol ( = 0.057; p = n.s.), or BMI ( = 
-0.109; p = n.s.). Medication adherence also did not differ significantly across BMI categories 
(2(2) = 2.518; p = n.s.) 
Cerebrovascular Factors. Correlation coefficients for cerebrovascular and behavioral 
variables are presented in Table 7. Cerebrovascular risk, as measured by overall burden of WMH, 
was also not significantly associated with medication adherence  
( = -0.015; p = n.s.) among the sample.  
Depression. Overall depression scores on the GDS were not significantly correlated with 
medication adherence ( = -0.021; p = n.s.). Similarly, percent of missed doses did not vary based 
on clinical cut-offs for depression; participants who reported minimal depressive symptoms had 
similar levels of adherence to those who endorsed mild levels of depression (U = 325.00; p = n.s.). 
Alcohol Use. Self-reported alcohol use was also not significantly associated with 
adherence among the sample ( = -0.019; p = n.s.) and those who reported clinically significant 
levels of alcohol-related problems did not miss a significantly higher percentage of their 
antihypertensive medication doses than those participants who reported minimal alcohol-related 
problems (U = 125.00; p = n.s.). 
Neuropsychological Risk Factors.  
Estimated Cognitive Ability. The relationship between adherence and estimated premorbid 
cognitive functioning was assessed using Spearman’s rank correlation coefficients. There was no 
statistically significant association between adherence to antihypertensive medications and WTAR 
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scores ( = 0.025; p = n.s.). The correlation between adherence and estimated FSIQ scores was 
also non-significant ( = -0.072; p = n.s.).  
Predicting Adherence. A series of negative binomial regressions predicting medication 
adherence from individual tests of executive functioning were conducted, as discussed above. 
Based on the lack of significant associations described above, no demographic variables, 
medication-related factors, clinical characteristics or estimated cognitive ability scores were 
retained as covariates. Exponentiated beta coefficients and 95% confidence intervals for each 
model predictor are listed in Table 8.  
Composite EF. Composite EF scores were significantly predictive of better adherence to 
antihypertensive medications in the three months following baseline neuropsychological testing 
(Exp() = 0.926; 95% CI: 0.870–0.985; p = 0.014). For every one-point increase in composite EF 
score, the risk of a participant missing a percentage point of their medication doses decreased by 
7.4%, such that higher composite EF scores were predictive of better adherence within the current 
sample.  
Set-Shifting. Scores on Trails B significantly predicted better adherence to 
antihypertensive medications during the study period (Exp() = 0.974; 95% CI: 0.952–0.998; p = 
0.032). These results indicate that for every one-point increase in Trails B T-scores, the risk of a 
participant missing a percentage point of their medication doses decreased by 2.6%, such that 
higher Trails B scores predicted a smaller percentage of missed doses. However, when a difference 
score between Trails B and Trails A was calculated to account for variation in processing speed 
between participants and better isolate the mental flexibility and set-shifting aspect of Trails B, the 
difference between T-scores on Trails B and Trails A was not a significant predictor of adherence 
(Exp() = 0.977; 95% CI: 0.969–1.021; p = n.s.).  
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Information Updating and Monitoring. Digits Backward scores did not significantly 
predict the percentage of medication doses participants missed (Exp() = 0.963; 95% CI: 0.884–
1.049; p = n.s.). In contrast, however, when a difference score between Digits Backward and Digits 
Forward was calculated to better isolate the working memory component of this task, the 
difference between Digits Backward and Digits Forward was a significant predictor of adherence 
(Exp() = 0.907; 95% CI: 0.828–0.994; p = 0.037), such that for every one-point increase in the 
difference between Digits Backward and Digits Forward, participants were 9.3% less likely to 
miss a percentage of their medication. A larger positive difference between Digits Backward and 
Digits Forward (i.e., better working memory performance above and beyond basic attention) 
predicted better adherence.   
Inhibition. Interference scores on the Stroop task were also a significant predictor of 
medication adherence (Exp() = 0.960; 95% CI: 0.930–0.991; p = 0.013), such that for every one 
point increase in Stroop Interference T-scores, the risk of missing a percentage of prescribed doses 
decreased by 4.0%. No difference scores were assessed in secondary analyses, as Interference 
scores already account for expected performance based on word-reading and color-naming speed. 
Verbal Fluency. Neither FAS nor Animal T-scores were significant predictors of 
adherence (FAS: Exp() = 0.992; 95% CI: 0.969–1.014; p = n.s.; Animals: Exp() = 0.983; 95% 
CI: 0.958–1.010; p = n.s.). Medication adherence did not significantly change as verbal fluency T-
scores increased. 
 
Discussion 
The goal of this study was to evaluate the role of broad EF and specific executive processes 
in longitudinal adherence to antihypertensive medications among a sample of older adults with 
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HTN. We assessed the relationships between adherence, as based on proportion of prescribed pills 
that were returned, with the empirically-supported executive processes described in Miyake et al. 
(2000): set-shifting, information updating and monitoring, and inhibition. A total of 76 older 
adults, recruited as part of a broader randomized controlled trial assessing blood pressure control, 
participated in the study. Participants completed well-validated tests of set-shifting (Trails B), 
updating (Digits Backward), and inhibition (Stroop Interference), as well as EF measures that 
tapped into a combination of these processes (verbal fluency tasks).  
Rates of Adherence 
Results indicated that adherence to antihypertensive medication was quite good among our 
sample overall. More than 90% of participants maintained high levels of adherence (>85% of 
prescribed doses). Indeed, a sizeable proportion of the sample (35.5%) did not miss any of their 
prescribed antihypertensive doses during the study period. These results are at odds with many 
other studies that have demonstrated elevated levels of suboptimal adherence among individuals 
with HTN (Borzecki et al., 2005; Cramer et al., 2008; Kim et al., 2016b; Krousel-Wood et al., 
2009; Peacock & Krousel-Wood, 2017a; Pittman et al., 2010).  
This finding may be due in part to the nature of our sample. Because participants in the 
current study were enrolled in a broader HTN intervention trial, a number of well-established 
barriers to medication adherence were removed or substantially reduced by the study design. In 
contrast to individuals in studies that have shown generally poor adherence to antihypertensive 
medications, participants in the current study were provided with their medication free of charge 
and received refills during their study visits (Fitz-Simon, Bennett, & Feely, 2005; Krousel-Wood 
et al., 2009; Vrijens et al., 2008). Research indicates that cost and the logistics of picking up 
medications from the pharmacy can present substantial barriers to adherence among older adults 
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(Barnes & Lu, 2012; Khatib et al., 2014b; Ma, 2016; Peacock & Krousel-Wood, 2017b; Pham, 
Rosenthal, & Diamond, 1999; Zivin, Ratliff, Heisler, Langa, & Piette, 2010). By reducing these 
structural barriers, the design of the broader intervention trial may have helped to increase 
adherence in the current study to a level not typically observed in other samples.  
In addition, individuals in the current study had already taken significant steps toward 
managing their HTN, simply by being part of the broader intervention trial. As such, individual-
level factors that have been shown to be associated with lower rates of adherence, such as lack of 
knowledge about HTN, personal beliefs against using medication, indifference to asymptomatic 
conditions, and lack of motivation for self-care were likely less prevalent in our sample than in the 
general HTN population (Egan, Lackland, & Cutler, 2003; Egan, Zhao, & Axon, 2010; Molloy et 
al., 2009; Ogedegbe, Harrison, Robbins, Mancuso, & Allegrante, 2004; Yap et al., 2015b, 2015a).  
Demographic Risk-Factors. There were no significant associations between 
antihypertensive adherence and demographic variables within our sample. While we did not posit 
specific hypotheses regarding potential relationships between adherence and specific demographic 
characteristics, the lack of any such associations in our sample was somewhat surprising, 
particularly given existing literature that has suggested that age, gender, race and ethnicity, and 
level of education can be related to medication adherence among elderly adults with HTN (Burnier 
& Egan, 2019; Gellad et al., 2011; Holt et al., 2013; Krousel-Wood et al., 2009; Lewis, 2012; Yap 
et al., 2015b). The fact that our sample was comprised of individuals who had already sought out 
and consented to participate in clinical research and subsequently received a great deal of support 
around medical appointments and access to medication may have played a role in the lack of 
significant associations between adherence and demographics observed in our study. It is possible 
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that among a sample of individuals who are motivated to better manage their HTN and who are 
highly supported in their efforts to do so, such demographic variables become less salient.  
Medication-Related Risk Factors. Medication-related factors, such as changes in number 
of antihypertensive doses per day, prescription regimen, and number of daily HTN medications 
were also not associated with adherence. While other studies have indicated that medication 
regimen complexity and number of pills can negatively impact adherence among older adults, most 
of our participants did not have particularly complex antihypertensive medication regimens 
(Alghurair et al., 2012; Gellad et al., 2011; Topinkova, Baeyens, Michel, & Lang, 2012; van der 
Laan et al., 2017). The fact that most participants were prescribed relatively few doses overall and 
received support around changes in medication regimen (i.e., returning their unused medication to 
avoid confusion), may have attenuated these relationships in our sample.  
Clinical Risk-Factors. Similarly, our study did not find evidence of any significant 
associations between adherence and other clinical characteristics, such as HTN severity, 
cholesterol levels, BMI, WMH volume, depression, or alcohol use. It seems quite possible that the 
internal motivation and external support within a clinical research sample such as ours may have 
helped to attenuate some of the risks associated with greater disease co-morbidity, which have 
been identified elsewhere (Choi et al., 2018; van der Laan et al., 2017; Yap et al., 2015b). In 
addition, our sample demonstrated quite low levels of behavioral health risk factors for poor 
adherence; on average, our sample was not depressed and consumed relatively low levels of 
alcohol. Exclusion criteria for the broader study also served to reduce the prevalence of significant 
medical co-morbidity in our sample. Thus, while all the participants in the current study had 
documented HTN and cerebrovascular disease, on average they did not demonstrate high levels of 
complicating medical or behavioral co-morbidities, which may have also attenuated relationships 
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between adherence and physical and behavioral health that have been demonstrated in other studies 
but were not observed here.  
Executive Functioning 
 Overall cognitive functioning among participants was estimated to be in the high average 
range, consistent with participants’ relatively high levels of education. Overall, participants 
performed in the average range on all tests of executive functioning included in the study battery, 
within normative expectations based on their estimated cognitive abilities.  
 The Role of Composite EF. Our hypothesis that composite EF scores would predict 
antihypertensive medication adherence over the three-month study period was supported; for every 
one-point increase in composite EF score, the risk of a participant missing a percentage point of 
their medication doses decreased by 7.4%. Thus, compared to an individual whose performances 
across all five tests of EF were consistently in the low average range (z-scores of -1.0 on each test), 
a participant whose performances were consistently average (z-scores of 0.0 on each test), would 
be 37% less likely to miss a percentage point of their medication doses over the course of the study. 
Risk of missing medication doses would continue to decline as composite EF increased, such that 
an individual with consistently high average EF scores (z-scores of +1.0 on each test) would be 
nearly 75% less likely to miss a percentage point of their medication doses compared to their low-
average peer. This finding is consistent from studies of older adults with chronic medical 
conditions that has suggested that overall EF ability plays an important role in medication 
adherence (Barclay et al., 2007; Ettenhofer, Foley, Castellon, & Hinkin, 2010; Insel et al., 2006; 
Munshi et al., 2012; Nguyen et al., 2010).  
 In addition to extending the existing literature on EF and medication adherence to older 
adults with HTN, the current study also sought to explore associations between adherence and 
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specific executive processes to examine potentially differential effects. We hypothesized that tests 
of these individual executive processes (i.e., set-shifting, information updating, and inhibition), as 
well as tests that tapped into multiple processes (i.e., verbal fluency tasks), would each be 
significantly predictive of better adherence.  
 The Role of Set-Shifting. Our hypothesis that set-shifting ability, as measured by Trails 
B, would predict antihypertensive adherence initially appeared to have been supported in the 
current study. However, after adjusting for overall processing speed to better isolate the set-shifting 
component of the test, the difference between Trails A and Trails B performance was not 
significantly predictive of antihypertensive medication adherence. The finding that processing 
speed, rather than pure mental flexibility and set-shifting ability, predicted antihypertensive 
adherence in our sample ran counter to our expectations, as well as a number of studies among 
other populations that have identified poor set-shifting and mental flexibility as a risk factor for 
poor adherence (Manning et al., 2012; Munshi et al., 2012; Rosen et al., 2003; Stilley et al., 2010; 
Stoehr et al., 2008). 
 A Possible Role for Processing Speed? Importantly, however, among those studies that 
have demonstrated significant associations between Trails B performance and adherence, only one 
also sought to isolate the set-shifting component of the task by evaluating the difference between 
Trails A and B (Munshi et al., 2012). Thus, it may be possible that results from previous studies 
linking Trails B performance to medication adherence may have been driven more by the 
processing speed component of the task than by the set-shifting component. Indeed, one study that 
examined medication adherence across multiple chronic illnesses indicated that attention and 
processing speed measures were more consistently associated with adherence than mental 
flexibility (Stilley et al., 2010). Evidence from a study of older adults with cardiovascular risk 
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(heart failure), in which Trails A, but not Trails B, was predictive of medication adherence, lends 
further support to this consideration (Alosco et al., 2012).  
 It also seems reasonable to consider that processing speed could play a role in medication 
adherence (Alosco et al., 2012; Brandt & Manning, 2009; Ettenhofer et al., 2009; Munshi et al., 
2012) and may interact with EF and specific executive processes in important ways. For example, 
slowed processing speed likely places greater demands on working memory; it may be harder to 
update and monitor information when speed of processing is slow because information would need 
to be held in mind for longer periods of time (Albinet, Boucard, Bouquet, & Audiffren, 2012; 
Stawski, Sliwinski, & Hofer, 2013). In this way, the impact of speed of processing on medication 
adherence could potentially be mediated by executive processes. The shared neural substrates of 
these cognitive domains also suggest a strong association; processing speed is highly correlated 
with white matter integrity in the brain and intact white matter, particularly in frontal and parietal 
regions, has been shown to be integral to higher order cognitive functions (Albinet et al., 2012; 
Jacobs et al., 2013; Kerchner et al., 2012; Li et al., 2015; Lovden et al., 2014; Perry et al., 2009).   
 In addition to the potential importance of processing speed, the lack of a significant 
association between set-shifting and adherence in our sample could be related to participants’ 
involvement in the broader intervention study. The proposed model put forth in this paper 
highlights the role set-shifting could play in addressing barriers to adherence, such as the ability 
to problem-solve around issues of consistent access to medication, which were deliberately 
diminished in the intervention trial (e.g., medications were provided at study visits free of charge, 
participants received reminder calls for appointments, transportation arrangements were made for 
visits where needed). Although set-shifting would still seem to play a role in some of the day-to-
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day flexibility required to adhere to medication, is possible that the reduction of these barriers may 
have attenuated the relationship between set-shifting and overall adherence in the current study.  
The Role of Information Updating. We also hypothesized that information updating, as 
measured by the Digits Backward task, would predict adherence to antihypertensive medications 
among our sample. This hypothesis did not initially appear to have been supported by the data, as 
normed Digits Backward scores alone did not significantly predict percentage of missed doses. 
However, when scores were adjusted for Digits Forward performance to better isolate the 
updating/working memory component of the task, difference scores between Digits Backward and 
Digits Forward were significantly predictive of adherence and a larger positive difference between 
Digits Backward and Digits Forward predicted better adherence. These findings are consistent 
with our hypothesis and suggest that the specific ability to manipulate information, that is to say, 
to update information, rather than just maintain it in mind, is particularly important for adherence.  
Working memory performance, above and beyond basic attention, had a significant impact 
on adherence in the current study. Scoring one standard deviation (three scaled score points) higher 
on Digits Backward than on Digits Forward corresponded to a nearly 30% lower risk of missing a 
percentage of medication doses over the course of the study. For instance, a participant taking one 
pill per day with Digits Backward performance in the high average range (scaled score of 13) and 
Digits Forward performance in the average range (scaled score of 10) would be about 28% less 
likely to miss a dose of their medication compared to a participant whose normed Digits Forward 
and Digits Backward scores were comparable (e.g., both scaled scores of 10). These results were 
consistent with other studies among older adults (Alosco et al., 2012; Manning et al., 2012; Stilley 
et al., 2010) that have demonstrated associations between adherence and working 
memory/updating tasks. 
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Our finding supports the idea that the ability to monitor and update mental information 
plays an important role in medication adherence. Even though participants in our study had many 
barriers to adherence reduced or removed (e.g., did not need to monitor when prescriptions had to 
be refilled), a number of tasks that could reasonably be supposed to rely on information updating 
ability remained for them to overcome. For instance, our model proposes that information updating 
could facilitate self-monitoring of medication-taking behaviors, a facet of adherence that 
participants in our study had to manage themselves. Participants’ ability to revise and replace 
mental representations of their most recent instance of dose-taking would have continued to be 
important in order for them to avoid missing pills or accidentally double-dosing.  
In addition, our participants also needed to maintain and update their intention to adhere to 
their antihypertensive medications, both over time and in the face of distractions. Other research 
has emphasized the role of working memory and updating abilities in acting on intention and 
executing planned activities (Barrett et al., 2004; Basso et al., 2010; Kliegel et al., 2002, 2000; 
McDaniel & Einstein, 2011), and our proposed model suggests this could be an important way in 
which information updating impacts medication adherence. Although our study did not test these 
specific model-based hypotheses directly, the fact that information updating was significantly 
associated with adherence among our sample indicates that these behaviors may be potential 
mechanisms of action by which updating/working memory ability impacts medication adherence.   
The Role of Inhibition. Our hypothesis that inhibition, as measured by Stroop Interference 
scores, would predict adherence to antihypertensive medications was also supported in our sample. 
Scoring one standard deviation (10 points) higher on Stroop Interference performance 
corresponded to a 40% lower risk of missing a percentage point of medication doses over the 
course of the study. Thus, a participant taking one pill per day with a Stroop Interference 
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performance in the high average range (T-score of 60) would be about 40% less likely to miss a 
dose of their medication compared to a participant with a similar medication regimen who 
performed in the average range for Stroop Interference (T-score of 50). These results were 
consistent with other studies that have demonstrated associations between adherence and 
inhibitory ability (Barclay et al., 2007; Zartman, 2007). 
Similar to our information updating/working memory findings, these results indicate that 
inhibition seems to play a meaningful role in the ability to adhere to antihypertensive medications. 
Returning to our proposed model, inhibitory control may have impacted our participants’ ability 
to adhere to their medications through multiple behaviors. For instance, our participants needed to 
inhibit retrospective interference from prior memories of taking their medication, to know that 
they still needed to take their medication. Without the ability to inhibit existing mental 
representations of having taken their medications yesterday, they might mistakenly believe they 
had already taken their medications today, leading to a missed dose (Brock et al., 2012; Etienne et 
al., 2008). Inhibitory control may have also been important for our participants in filtering out in-
the-moment distractions (e.g., suppressing distraction from the television in the background), as 
well as restraining the potential impulse to avoid taking their medication in favor of more 
immediately appealing options (e.g., inhibiting the desire to skip a dose because taking their 
medications makes them “feel old”).  
Consistent with the current findings, theoretical models of other health behaviors such as 
exercise, dietary control, and alcohol use, have also suggested a central role for inhibitory ability 
(Dohle, Diel, & Hofmann, 2018; Fernie et al., 2013; Gettens & Gorin, 2017; Hall & Fong, 2013, 
2015; Hofmann et al., 2008). This is perhaps unsurprising when we consider that evidence suggests 
that inhibition is very closely tied with broad EF ability (Miyake & Friedman, 2012). Studies 
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exploring the relative contributions of specific executive processes to broad EF have indicated that 
inhibitory control overlaps with EF more than either set-shifting (which seems to also share 
variance with processing speed abilities) or information updating (which seems to seems to also 
share variance with long-term memory and controlled retrieval) (Miyake & Friedman, 2012). 
Thus, it makes sense that inhibition would play such a central role in activities that seem to require 
EF more broadly.  
The Role of Verbal Fluency. Our hypotheses regarding the role of verbal fluency were 
not supported in our sample, as neither phonemic/letter or semantic/category fluency performance 
were significantly associated with antihypertensive adherence over the course of the study. This 
finding is inconsistent with results from other studies that have identified significant associations 
between both phonemic fluency and adherence, and semantic fluency and adherence (Alosco et 
al., 2012; Bender et al., 2014; Klepin et al., 2014; Munshi et al., 2012), though other studies have 
failed to show such an association (Barclay et al., 2007).  
Verbal fluency tests were included in the current battery due to their reliance on multiple 
executive processes, as these tasks involve the ability to develop and initiate a strategic approach 
to the task, monitor one’s own performance for errors, inhibit responses that violate task rules, and 
switch strategies as required (Baldo & Shimamura, 1998; Diamond, 2014; Lezak et al., 2012; Shao 
et al., 2014). While it seems reasonable that such a test could relate to medication adherence ability, 
the lack of a significant association in our study is actually consistent with a broader trend in the 
literature that tests of more complex executive abilities have been shown to be less predictive of 
health behaviors (Hall & Fong, 2013). One possibility for this trend could be that as tests of EF 
become more multi-faceted and complex, they might also become more specific, such that they do 
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not map as well onto other behaviors and may be less generalizable (Chaytor, Schmitter-
Edgecombe, & Burr, 2006).  
Putting it All Together 
 To our knowledge, this is the first study to explore relationships between both broad EF 
and specific executive processes and adherence to antihypertensive medications in a sample of 
older adults with HTN. Our findings support a role for EF in medication adherence, even in a 
situation where many systematic barriers to adherence were substantially reduced (i.e., within a 
medication intervention trial) and adherence broadly was quite high. Information updating ability 
and inhibitory control were particularly important to longitudinal adherence in our sample, while 
set-shifting and verbal fluency were not significantly associated with missed doses.  
Though only partially expected based on our hypotheses, these findings are in accord with 
much of the broader existing literature on the role of EF in various health behaviors; inhibition and 
working memory processes have been most consistently linked with a range of health behaviors, 
while shifting and higher-order executive abilities have demonstrated less predictive power (Hall 
& Fong, 2013). Based on this general trend, information updating and inhibitory control have been 
incorporated into multiple theoretical models of health behaviors (Dohle et al., 2018; Hall & Fong, 
2010, 2013, 2015; Hofmann et al., 2008). Although these models differ in their subtleties, each 
suggests that inhibition and working memory interact to moderate the relationship between 
behavioral intentions and actual health behaviors, as well as exerting some degree of direct 
influence on health behaviors themselves (Dohle et al., 2018; Hall & Fong, 2010, 2013, 2015; 
Hofmann et al., 2008).  
A Model of EF and Adherence, Revisited. While these theoretical models have suggested 
mechanisms for inhibition and working memory in health behaviors generally, none have 
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considered the specific case of medication adherence or the ways in which executive processes 
could impact adherence through specific behaviors (e.g., self-monitoring). Though aspects of our 
proposed conceptual model of executive processes and adherence (Figure 1) were not supported 
in the current study (i.e., set-shifting did not significantly predict adherence), the significant 
Set-Shifting 
Updating and 
Monitoring 
Information 
Inhibition 
o Adjust to schedule changes 
o Problem-solve around 
potential barriers to access 
(e.g., transportation) 
o Adapt to changes in 
medication regimen 
o Transition away from 
previous medication-taking 
habits 
 
 Self-monitor medication-
taking behavior 
 Arrange for continuous 
access to medications 
 Maintain intention to adhere 
over time, distractions 
 Role in prospective memory 
 
 Suppress distraction, 
retrospective interference 
 Implement adherence plans 
in place of more immediately 
rewarding activities 
 Suppress desire to not take 
meds due to inconvenience, 
side effects, etc.  
 
Figure 2. Conceptual model adjusted to reflect the lack of significant association between set-
shifting and adherence in the current study. The observed associations between sustained adherence 
and both updating/monitoring information and inhibition and adherence could be facilitated by 
these proposed behaviors.  
Sustained  
Anti-
hypertensive 
Adherence 
Executive Processes        Adherence Behaviors 
    (Miyake et al., 2000) 
 
  
   60 
associations we identified between adherence and information updating and inhibition suggest that 
adherence-related behaviors that are influenced by these specific abilities could be particularly 
important for sustained medication use (Figure 2). A comprehensive examination of the model-
based behavioral mechanisms of sustained antihypertensive adherence was beyond the scope of 
this study. However, our model, revised to reflect the current results, nonetheless provides a 
possible roadmap for future research into the ways in which particular executive processes may 
moderate specific medication-taking behaviors. 
A Bidirectional Relationship? The literature on EF and health behaviors had evidenced 
much debate regarding the directionality of this relationship (Allan et al., 2016; Hall & Marteau, 
2014). Some researchers have argued that better or worse initial EF predicts subsequent 
engagement in healthy behaviors, or lack thereof, while others have noted that health behaviors 
likely impact subsequent EF (Allan et al., 2016; Fernie et al., 2013; Gujral, McAuley, Oberlin, 
Kramer, & Erickson, 2017; Hall & Marteau, 2014; McAuley et al., 2011). The longitudinal design 
of the current study allows us to clarify at least one component of this debate; our findings support 
a predictive relationship between baseline EF and subsequent adherence. It should be noted, 
however, that our findings do not in any way preclude the possibility of a bidirectional or reciprocal 
relationship, and it is very possible, indeed very likely, that adherence to antihypertensive 
medication also predicts later EF scores. 
Models of the role of EF in physical exercise and problematic alcohol use have each 
suggested positive and negative feedback loops between EF and these behaviors, such that worse 
EF predicts poorer health behaviors, and the impact of these health behaviors on biological 
substrates, particularly within the frontal lobes, then negatively impact EF, creating a kind of 
“vicious cycle” (Allan et al., 2016; Hall & Marteau, 2014). Conversely, a positive feedback loop 
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also seems to exist for both alcohol use and physical exercise, with better EF predicting better 
health behaviors, and those behaviors then predicting subsequently preserved or improved EF 
(Allan et al., 2016; Fernie et al., 2013; Hall & Marteau, 2014).  
It is not difficult to see how such a model could easily be extended to EF and medication 
adherence (Figure 3). Our study supports a relationship between higher initial EF and better 
subsequent medication adherence. As discussed above, a large body of literature has linked 
antihypertensive adherence among older adults with positive cardiovascular and cerebrovascular 
outcomes, which in turn help to protect neurological substrates of EF (Abraham et al., 2016; 
Lionakis et al., 2012; Naderi et al., 2012; Peacock & Krousel-Wood, 2017a; Yu et al., 2011). These 
data suggest a positive feedback loop for EF and adherence to antihypertensive medications. At 
the same time, lower initial EF in our study was associated with greater difficulty adhering to 
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antihypertensive medications. Individuals who exhibit suboptimal adherence are also more likely 
to have uncontrolled BP, which can then negatively impact neurological substrates of EF via 
damage to cerebrovascular systems (Abraham et al., 2016; Khan et al., 2007; Krousel-Wood et al., 
2009; Lionakis et al., 2012; Naderi et al., 2012). Indeed, white matter damage secondary to HTN 
seems to occur disproportionately in the frontal and parietal lobes, and white matter disease has 
been strongly linked to declines in EF (De Leeuw et al., 2001; Papp, Kaplan, & Snyder, 2011; 
Verhaaren et al., 2013; Wakefield et al., 2010). These findings, in conjunction with our own results, 
support the existence of a similarly reciprocal negative feedback loop for EF and antihypertensive 
adherence.  
Implications for Clinical Practice. Importantly, research has indicated that there are ways 
to improve EF in older age, so these feedback loops do not necessarily represent inevitable 
trajectories. Although improving EF remains a novel area of investigation, preliminary evidence 
indicates that certain interventions can reliably increase EF performance among the elderly 
(Diamond, 2014; Karbach & Verhaeghen, 2014; Lövdén et al., 2010). Mindfulness-based stress 
reduction, computerized training programs, and physical activity have all been shown to improve 
executive processes among older adults (Brehmer, Westerberg, & Bäckman, 2012; Karbach & 
Verhaeghen, 2014; Lövdén et al., 2010; Richmond, Morrison, Chein, & Olson, 2011; Scherder et 
al., 2014; Voss, Nagamatsu, Liu-Ambrose, & Kramer, 2011). Physical activity seems particularly 
promising, as exercise interventions produce gains across multiple EF domains that generalize to 
new tasks and persist over time (Best et al., 2014; Erickson & Kramer, 2009; McAuley et al., 2011; 
Scherder et al., 2014; Voss et al., 2011). Importantly, one exercise study found that the increases 
in EF resulting from exercise were predictive of subsequent adherence to the exercise intervention 
itself, suggesting that exercise may produce similar improvements in medication adherence (Best 
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et al., 2014). Although no studies have yet investigated the impact of EF improvement on 
medication adherence, these results are promising.  
Our study results also suggest that brief, easy-to-administer tests can be sensitive to 
processes that significantly predict sustained medication adherence among older adults with HTN. 
As such, inclusion of performance-based tasks that tap into these executive processes may be 
useful additions to primary care cognitive screens, particularly when sub-optimal adherence is 
reported or suspected. Screening for deficits in updating/working memory or inhibitory control in 
the context of routine clinical practice may be particularly useful for identifying patients who may 
be less able to adhere to their medications as prescribed. By identifying patients who may be at 
greater risk for suboptimal adherence due to poor EF, prescribers can intervene and provide 
targeted support around medication-taking behaviors.  
Limitations of the Current Study 
 The current study should be considered in the context of certain limitations. First, there 
may be characteristics of the current sample that influenced our outcomes in such a way as to limit 
generalization to other populations. As noted above, participants in this study were drawn from a 
broader study sample for whom many prominent barriers to medication adherence were 
diminished. Due to participation in the broader intervention study, participants in the current study 
received their antihypertensive prescriptions free of charge, without having to arrange for refills, 
and in the context of high levels of care connection (e.g., frequent doctor visits, appointment 
reminders, arrangements for transportation if necessary). As such, the current findings may not 
generalize to other populations for whom access to care and the logistics of medication adherence 
remain substantial barriers, regardless of EF. At the same time, the reduction of these barriers in 
our study helps us to be more confident that problems with adherence in our sample were not 
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secondary to a systematic barrier, like prescription cost. In addition, though all our participants 
had hypertension and measurable cerebrovascular disease, the sample was still fairly high 
functioning in ways that may not generalize to those with more complex presentations. For 
instance, on average, participants in our study were well educated, and no participants had 
significant levels of depression (moderate or higher) or dementia. While these findings may limit 
generalizability to more psychiatrically or cognitively impaired individuals, it may also have 
increased our power to detect the relationships between EF and adherence, which could have been 
washed out in individuals with broad cognitive or psychiatric impairment.  
 Secondly, quantitative assessment of medication adherence presents a methodological 
challenge. There is no perfect method by which to assess medication adherence in this population, 
and estimates of adherence can vary substantially with different measures of adherence (Baek, 
2014; Ettenhofer et al., 2009; Levine et al., 2006; Stilley et al., 2010; Vaughan & Giovanello, 
2010). Although our use of pill counts is considered to be a more objective and reliable method of 
adherence assessment, some researchers have raised concerns about the validity of this method, as 
there is no way to assure that “used” pills were actually taken by the patient, and social desirability 
could lead participants to dump remaining pills before counts are conducted (Kalichman et al., 
2007; Osterberg & Blaschke, 2005; Williams et al., 2013). Pill counts also do not provide 
information about dose timing, which can be important in HTN (Ho, Bryson, & Rumsfeld, 2009; 
Whelton et al., 2018). In addition, we adopted the conservative approach that individuals who 
failed to return certain prescriptions were perfectly adherent to that medication. While this method 
helped us to have confidence that our results were not due to mistakenly underestimating 
adherence, it is possible that we could have overestimated adherence in our sample, particularly as 
it is reasonable to suppose that those individuals who forgot to bring their medications to their 
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appointment may also have been more forgetful in adhering (Pullar, Kumar, Tindall, & Feely, 
1989).   
 Thirdly, the current study was constrained by the data collected as part of the broader study. 
As a result, it was not possible to assess for other health conditions have may have impacted EF 
(e.g., ADHD, history of head injury). Data regarding patients’ other medications were also 
unavailable, making it impossible to assess or control for their other medication-taking behaviors. 
As a result, we are not able to speak to their broader medication adherence and whether they may 
have been differentially adherent to different medications. We are also unable to fully consider the 
overall burden of their medication regimen, which is a major independent risk factor for poor 
adherence (Doggrell, 2010; Hain et al., 2012; Pasina et al., 2014; Yap et al., 2015b), and has been 
shown to interact with impaired EF to increase the likelihood of poor adherence (Ettenhofer et al., 
2009; Hinkin et al., 2002).   
 Lastly, due to time constraints, the three primary executive processes in our study, set-
shifting, information updating, and inhibition were each only assessed with one measure. While 
clinically sensitive and psychometrically sound, these tests are also subject to the problem of “task 
impurity,” as tests overlap with and rely on other cognitive abilities (e.g., language, memory, 
sensorimotor skills) (Chan, Shum, Toulopoulou, Chen, 2008). The problem of task impurity could 
have been exacerbated because only one test was used to assess each executive process. To address 
this concern, post-hoc analyses were conducted to isolate the processes of interest wherever 
possible (i.e., difference between Trails A and B to isolate set-shifting, difference between Digits 
Forward and Digits Backward to isolate updating/working memory, calculating Stroop 
Interference scores rather than using non-adjusted scores). However, although language and 
memory functions were not assessed in the current study, it is possible that contributions from 
  
   66 
these functions could have impacted the observed relationships to some degree because of the 
“impurity” of EF measures.  
 
Conclusions 
Despite these limitations, the current study contributes to the existing literature on EF and 
medication adherence in important ways. This is the first study to demonstrate a significant 
longitudinal relationship between baseline EF, as well as the specific processes of information 
updating and inhibitory control, and antihypertensive adherence in a sample of older adults with 
HTN. Our proposed conceptual model, in conjunction with the demonstrated associations between 
adherence and the specific executive processes of information updating and inhibition, generates 
a number of new hypotheses and provides a roadmap for future research into theory-driven 
examinations of the behavioral mechanisms by which EF can impact adherence. Our work also 
extends the literature on the directionality of relationships between EF and health behaviors, and 
provides a starting point for exploring the possibility of reciprocal feedback loops in EF and 
medication adherence, similar to those demonstrated for EF and other health behaviors. Further 
work extending the current findings on EF and medication adherence outside the context of a 
clinical research study is also needed to help increase the generalizability of these findings.  
Perhaps most importantly, our study suggests that screening for deficits in information 
updating and inhibitory control may help to identify patients at risk for suboptimal 
antihypertensive adherence, which is associated with significant risk for cardiovascular and 
cerebrovascular morbidity and mortality. Providers can then intervene to better support 
antihypertensive medication adherence among older HTN patients at elevated risk for suboptimal 
adherence due to poor EF. Our findings also raise the possibility that interventions to enhance EF, 
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such as physical exercise, could be used to positively impact medication adherence among older 
adults with HTN as well. Future research is needed to extend these theoretical and clinical 
considerations, but our findings are promising for increasing our understanding and developing 
tools to improve medication adherence among this vulnerable population. 
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Table 1. Sample Demographic Characteristics 
Characteristic n or Mean % or SD  
Age (years) M: 81.51 SD: 4.48  
Gender 
     Male  
     Female 
 
40 
36 
 
52.6% 
47.4% 
 
Race/Ethnicity  
     White/Caucasian 
     Black/African American       
     Hispanic/Latino/a  
     Asian/Asian American  
 
65 
6 
4 
1 
 
85.5% 
9.2% 
5.3% 
1.3% 
 
Handedness 
     Right 
     Left 
     Ambidextrous 
 
69 
7 
0 
 
90.8% 
9.2% 
0% 
 
Education (years) 
     Less than 9 
     9 to 11 
     12 (High School Graduate) 
     13-15 
     16 (Bachelor’s Degree) 
     More than 16 
M: 15.22 
3 
2 
11 
15 
22 
23 
SD: 3.04 
3.9% 
2.6% 
14.5% 
19.7% 
28.9% 
30.3% 
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Table 2. Participant Medication Usage 
 n or Mean % or SD  
Weighted # of Doses per Day M: 2.62 SD: 1.36  
Change in Medication Regimen 
     Dosage Change 
     New Medication  
     Medication Removed  
     Switch Medication 
     Frequency Change 
     More Than One Change 
50 
31 
22 
7 
5 
4 
19 
65.8% 
40.8% 
28.9% 
9.2% 
6.6% 
5.3% 
25.0% 
 
Max. # of Daily Medications  
     One 
     Two 
     Three 
     Four 
     Five 
M: 2.47 
10 
34 
21 
8 
3 
SD: 0.99 
13.2% 
44.7% 
27.6% 
10.5% 
3.9% 
 
Medications Prescribed to Pts      
     Amlodipine 
     Losartan 
     Lisinopril 
     Hydrochlorothiazide 
     Metoprolol 
     Doxazosin 
     Furosemide 
     Spironolactone 
 
55 
35 
32 
26 
24 
11 
6 
5 
 
72.4% 
46.1% 
42.1% 
34.2% 
31.6% 
14.5% 
7.9% 
6.6% 
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Table 3. Baseline Clinical Characteristics 
Characteristic  n or Mean % or SD Range  
Systolic BP (mm Hg, 24-hour average)  151.54 12.52 123 – 186  
Diastolic BP (mm Hg, 24-hour average)  74.83 9.00 56 – 94  
Heart Rate (beats per minute; 24-hour average)  67.53 8.50 51 – 89  
Total Cholesterol (mg/dL)  
     HDL Cholesterol (mg/dL)  
     LDL Cholesterol (mg/dL)  
179.83 
55.16 
103.95 
41.76 
15.86 
32.81 
113 – 211 
27 – 104 
27 – 191 
 
Body Mass Index (kg/m2) 
     Underweight (<18.5)  
     Normal Weight (18.5 – 24.9) 
     Overweight (25 – 29.9) 
     Obese (30+) 
27.76 
0 
22 
25 
29 
5.02 
0% 
28.9% 
32.9% 
38.2% 
19 – 41 
-----   
----- 
----- 
----- 
 
White Matter Hyperintensity Burden  
(% of intracranial cavity)  
1.49 
 
1.15 
 
0.523 – 6.262 
 
 
Depressive Symptoms  
     Minimal/Non-Depressed 
     Mild  
     Moderate 
     Severe 
M: 4.84 
64 
11 
0 
0 
SD: 4.09 
84.2% 
14.5% 
0% 
0% 
0 – 19 
-----   
----- 
----- 
----- 
 
Alcohol Use 
     AUDIT < 8 
     AUDIT  8 
M: 2.56 
72 
4 
SD: 2.73 
94.7% 
5.3% 
0 – 15 
----- 
----- 
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Table 4. Baseline Neuropsychological Functioning 
Characteristic (range) Mean SD Range  
WTAR (Standard Score)*  
     Estimated FSIQ  
113.76 
112.32 
14.17 
12.12 
69-128 
77-126 
 
Composite EF (sum of 5 z-scores) 0.36 3.36 -8.9-6.2  
Trails A (T-Score)  53.93 8.21 16-65  
Trails B (T-Score)  50.54 10.64 14-63  
Digits Forward (Scaled Score)  9.51 2.79 6-19  
Digits Backward (Scaled Score)  9.76 2.76 5-18  
Stroop Word Reading (T-Score)  43.33 8.47 27-66  
Stroop Color Naming (T-Score)  40.78 7.18 21-58  
Stroop Color-Word Condition (T-Score)  47.31 9.07 20-69  
Stroop Interference (T-Score) 53.78 6.41 32-73  
Phonemic Fluency (FAS; T-Score)  47.57 10.64 24-76  
Semantic Fluency (Animals; T-Score)  50.38 11.49 17-77  
* Standard scores have a mean of 100 and standard deviation of 15. Z-scores have a mean of 0 and 
a standard deviation of 1.0. T-scores have a mean of 50 and a standard deviation of 10. Scaled 
scores have a mean of 10 and a standard deviation of 3.  
 
 
 
Table 5. Percent of Doses Missed 
 n or Mean % or SD  
Percent of Doses Missed M: 6.32% SD: 10.35  
     0%  
0.1 – 5.0%  
5.1 – 10.0% 
10.1 – 15.0% 
15.1 – 30.0% 
> 30.0% 
27 
19 
15 
8 
3 
4 
35.5% 
25.0% 
19.7% 
10.5% 
4.0% 
5.3% 
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Table 6. Associations between adherence and cardiovascular variables 
 
24-hr 
Systolic BP 
24-hr 
Diastolic BP 
24-hr Heart 
Rate 
Total 
Cholesterol 
HDL 
Cholesterol 
LDL 
Cholesterol 
BMI 
% of Doses Missed        
   Spearman Correlation -0.004 0.010 0.021 0.089 0.191 0.057 -0.109 
   Significance (2-tail) n.s. n.s. n.s. n.s. n.s. n.s. n.s. 
 
 
 
 
Table 7. Associations between adherence and cerebrovascular and behavioral health variables 
 
WMH  
(%ICC) 
GDS AUDIT  
% of Doses Missed     
   Spearman Correlation -0.015 -0.021 -0.019  
   Significance (2-tail) n.s. n.s. n.s.  
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Table 8. Predicting adherence from EF scores 
 Exp() 95% CI Low 95% CI High p 
Composite EF 0.926 0.870 0.985 0.014* 
Trails B 0.974 0.952 0.998 0.032* 
     Trails B - Trails A 0.977 0.969 1.021 0.265 
Digits Backward 0.963 0.884 1.049 0.383 
     Digits Backward - Forward 0.907 0.828 0.994 0.037* 
Stroop Interference 0.960 0.930 0.991 0.013* 
COWA 0.992 0.969 1.014 0.462 
Animals 0.983 0.958 1.010 0.210 
* p < 0.05 
 
 
  
   100 
Appendix 1. Current sample compared to those from broader study who were not included 
Variable 
Mean or N 
(Included) 
Mean or N 
(Excluded) 
t or 2 p (2-tailed) 
Age 81.23 80.18 -1.745 0.083 
Education 15.22 15.13 -0.337 0.736 
Gender (female) 36 69 0.574 0.339 
WMH (% ICCV) 1.50 1.35 -0.864 0.389 
Systolic BP 151.54 148.30 -1.783 0.076 
Diastolic BP 74.83 73.92 -0.767 0.444 
Heart Rate 67.53 68.70 0.701 0.484 
Total Cholesterol 179.83 182.98 0.408 0.683 
HDL Cholesterol 55.16 58.837 1.488 0.138 
LDL Cholesterol 103.95 104.76 0.026 0.979 
BMI 27.76 27.96 0.272 0.786 
GDS Total Score 4.84 3.76 -2.071 0.040* 
AUDIT 2.56 2.31 -0.815 0.416 
     
WTAR 
 (Standard Score) 
113.76 115.16 0.516 0.606 
Trails A  
(T-score) 
53.93 52.86 -0.150 -0.210 
Trails B  
(T-score) 
50.54 53.21 0.637 0.525 
Digit Span Forward  
(Scaled Score) 
9.51 9.75 0.350 0.727 
Digit Span Backward 
(Scaled Score) 
9.76 9.65 -0.429 -0.175 
Stroop Word Reading  
(T-score) 
43.33 43.59 0.430 0.668 
Stroop Color Naming 
(T-score) 
40.78 39.84 -0.652 0.515 
Stroop Color-Word 
Condition (T-score) 
47.31 45.65 -0.695 0.488 
Stroop Interference  
(T-score) 
53.78 53.17 -0.923 0.357 
Phonemic Fluency  
(FAS; T-score) 
47.57 45.72 -0.980 0.328 
Semantic Fluency  
(Animals; T-score) 
50.38 48.79 -1.022 0.308 
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Appendix 2. Drug Information 
Drug 
(other names) 
Drug Class 
Common Side 
Effects* 
Warning/Instructions 
Associated with Drug** 
Amlodipine 
(Norvasc) 
Calcium channel 
blocker 
Dizziness, 
lightheadedness, 
fatigue, stomach 
pain/nausea, swelling 
ankles/feet, flushing, 
headache 
- With or without food 
- Take at the same time 
each day 
- Avoid getting up too 
fast from sitting or 
lying down 
Losartan 
(Cozaar) 
Angiotensin II 
receptor antagonist 
Muscle cramps or 
weakness, diarrhea, 
heartburn, decreased 
sensitivity to touch 
 
 
- With or without food 
- Avoid getting up too 
fast from sitting or 
lying down 
Lisinopril 
(Qbrelis, Zestril, 
Prinivil) 
ACE inhibitor Stuffy nose, 
sneezing, sore throat, 
dry cough, muscle 
cramps, stomach 
pain, diarrhea, 
headache, dizziness, 
fatigue, sleep 
problems, rash 
- With or without food 
- Drink plenty of water 
Avoid getting up too fast 
from sitting or lying 
down 
Hydrochlorothiazide 
(Microzide) 
Thiazide diuretic Nausea, vomiting, 
loss of appetite, 
diarrhea, 
constipation, muscle 
spasms, dizziness, 
headache, hair loss 
 
- Do not take within one 
hour of taking 
cholestyramine or 
colestipol 
- Avoid alcohol 
- Avoid becoming 
overheated or 
dehydrated 
Metoprolol 
(Lopressor, Toprol 
XL) 
Beta-blocker Dizziness, fatigue, 
depression, 
confusion, memory 
problems, trouble 
sleeping, diarrhea, 
mild itching/rash, 
nausea, constipation, 
heartburn 
 
- Take with food or 
shortly after eating 
- Take at the same time 
each day 
- Avoid alcohol 
- Be careful when 
driving 
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Appendix 2, continued.   
Drug 
(other names) 
Drug Class 
Common Side 
Effects* 
Warning/Instructions 
Associated with Drug** 
Doxazosin 
(Cardura, 
Doxadura) 
1-selective 
adrenergic blocker 
Impaired reaction 
time, low blood 
pressure, dizziness, 
drowsiness, 
headache, feeling 
weak, fatigue, 
abnormal vision, 
weight gain 
 
- Avoid alcohol 
- Avoid becoming 
overheated or 
dehydrated 
- Be careful when 
driving 
- Avoid getting up too 
fast from sitting or 
lying down 
Furosemide 
(Lasix, Diaqua-2) 
Loop diuretic Diarrhea, 
constipation, 
numbness or 
tingling, headache, 
dizziness, blurred 
vision 
 
- High doses of 
furosemide may cause 
irreversible hearing loss 
- Do not take within 
two hours of sucralfate 
- Avoid becoming 
overheated or 
dehydrated 
- Avoid getting up too 
fast from sitting or 
lying down 
- Avoid alcohol 
Spironolactone 
(Aldactone) 
Aldosterone 
receptor antagonist 
Impaired reaction 
time, mild nausea or 
vomiting, diarrhea, 
breast swelling or 
tenderness, dizziness, 
headache, fatigue, 
drowsiness, leg 
cramps, difficulty 
having/maintaining 
an erection 
 
- With or without food, 
consistently 
- Take at the same time 
each day 
- Avoid salt substitutes 
high in potassium 
- Avoid a high salt diet 
- Be careful when 
driving 
- Avoid becoming 
overheated or 
dehydrated 
- Avoid getting up too 
fast from sitting or 
lying down 
*   This is an incomplete list and focuses on the most common routine side effects. It excludes 
side effects related to allergic reactions, drug interactions, or serious/life-threatening conditions 
that would necessitate immediate medical care. Side effects that could directly impact cognitive 
testing are bolded. 
** This is an incomplete list and excludes warnings for prescription drug interactions or 
precautions for specific medical conditions
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Appendix 3. Correlation Table of Neuropsychological Tests (normed) 
 
WTAR 
SS 
Trails 
A 
Trails 
B 
Digits 
Forward 
Digits 
Backward 
Stroop 
Word 
Stroop 
Color 
Stroop 
Color-
Word 
Stroop 
Inter-
ference 
Letter 
Fluency 
Category 
Fluency 
EF 
Composite 
WTAR SS ----- 0.083 0.388* 0.337* 0.450* 0.332* 0.174 0.403* 0.331* 0.232 0.16 0.484* 
Trails A  ----- 0.439* 0.145 0.251* 0.317* 0.244* 0.316* 0.167 0.220 0.249* 0.374* 
Trails B   ----- 0.342* 0.400* 0.454* 0.578* 0.670* 0.409* 0.325* 0.435* 0.811* 
Digits 
Forward 
   ----- 0.478* 0.349* 0.339* 0.341* 0.138 0.295* 0.131 0.431* 
Digits 
Backward 
    ----- 0.430* 0.370* 0.390* 0.157 0.280* 0.029 0.532* 
Stroop  
Word 
     ----- 0.695* 0.587* -0.011 0.300* 0.332* 0.548* 
Stroop  
Color 
      ----- 0.709* 0.113 0.259* 0.364* 0.581* 
Stroop 
Color-Word 
       ----- 0.745* 0.268* 0.321* 0.806* 
Stroop 
Interference 
        ----- 0.106 0.097 0.566* 
Letter 
Fluency 
         ----- 0.368* 0.597* 
Category 
Fluency 
          ----- 0.552* 
* p < 0.01; Bolded responses indicate correlations between EF measures 
 
 
 
